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ROLE OF NUDT+, MEDIATED ALTERNATIVE POLYADENYLATION AND 
HYALURONAN IN THE DEVELOPMENT OF PULMONARY HYPERTENSION 
Abstract 
Scott Dale Collum 
Advisory Professor: Harry Karmouty-Quintana Ph.D. 
 
 Pulmonary hypertension (PH) is a progressive disease with serious 
effects on quality of life and life expectancy of patients. PH is a complex 
disease that likely develops due to multiple influences, and no curative 
treatments exist for this disease. It has been shown that alternative 
polyadenylation (APA) due to depletion of Nudix Hydrolase +,(NUDT+,) is 
involved in several disease states including the chronic lung disease idiopathic 
pulmonary fibrosis (IPF). Additionally, hyaluronan, an extracellular matrix 
glycosaminoglycan has been associated with PH. The role and mechanism of 
NUDT+, and hyaluronan have not yet been described in this disease. My 
results reveal that NUDT+, depletion and APA in pulmonary artery smooth 
muscle cells (PASMCs) is associated with phenotypic changes and PH. I I also 
show that hyaluronan and hyaluronan related genes play important roles in 
the development of Pulmonary Arterial Hypertension (PAH) and PH 
associated with IPF and combined pulmonary fibrosis and emphysema. I also 
identify f-methylumbelliferone as an inhibitor of PH in this mechanism. These 
studies provide new mechanisms for understanding the development of PH 
and potential therapeutic targets.   
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Chapter 1: Introduction 
 
A portion of this chapter, including figure 1 is adapted from a review published 
in the Canadian Respiratory Journal. Collum SD, Amione-Guerra J, Cruz-Solbes AS, 
DiFrancesco A, Hernandez AM, Hanmandlu A, Youker K, Guha A, Karmouty-Quintana 
H. Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current 
and Future Perspectives. Can Respir J 2017 
 
 Pulmonary hypertension (PH) is a disorder of the lung vasculature. Clinically, 
PH is defined by an increase in mean pulmonary arterial pressure (mPAP) over 25 
mmHg accompanied by a pulmonary artery wedge pressure under 15 mmHg and an 
elevated pulmonary vascular resistance (1).  Physiologically PH includes remodeling and 
thickening of the pulmonary vasculature walls and a subsequent loss of luminal spaces. 
This loss of lumen and increase in pulmonary pressures cause an increased load on the 
right ventricle (RV). As the RV compensates aberrant remodeling occurs in the RV wall 
leading to hypertrophy and death by right-sided heart failure. The World Health 
Organization (WHO) classifies PH into five groups based on primary clinical diagnosis 
and histopathology (2). This study focused on two of the classifications; Group 1 or 
pulmonary arterial hypertension (PAH) which is not associated with other cardio-
pulmonary diagnosis and Group 3 or PH due to lung diseases including interstitial lung 
diseases such as idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary 
disease (COPD).  
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Group 1 PH 
 Group 1 PH includes several diagnostic groups; heritable pulmonary arterial 
hypertension, drug and toxin-induced PH, PH associated with connective tissue 
diseases devoid of lung involvement- and congenital heart disease associated PH. Total 
annual prevalence of Group 1 PH is estimated to be 40-127 cases per 100,000 in large 
cohort studies (3-5). Five-year survival rates are 69.4% after initial diagnosis (3). This 
classification group contains 69.9% females with a mean age of 50 years old (5). While 
there are no curative treatments for Group 1 PH, several drugs may increase survival 
time and quality of life in patients. The most common drugs are endothelin receptor 
antagonists, drugs targeting the nitric oxide pathway such as phosphodiesterase type 5 
(PDE-5) inhibitors or soluble guanylate cyclase activators, and prostanoids used as 
vasodilators (6-8). These treatments are given as monotherapies or in combination as 
the patient progresses (9). While strides have been made and these drugs may increase 
3 year survival rates by up to 70% in some cohorts this disease is still progressive and 
lung transplantation or death is the final outcome (10). In heritable cases of Group 1 PH 
a mutation of bone morphogenic protein receptor 2(BMPR2) is found in about 80% of 
cases while an additional 5% of cases are associated with other members of the 
transforming growth factor 𝛽 signaling pathway (11, 12). Many rare mutations are also 
associated with this heritable disease including mutations in caveolin-1 and activing-
like receptor kinase 1. Group 1 PH often presents with more severe pulmonary pressure 
changes and plexiform lesions than other classifications of pulmonary hypertension (1). 
Plexiform lesions are vascular structures of the pulmonary artery that are formed of 
proliferative and potentially phenotypically distinct endothelial cells, myofibroblasts 
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and smooth muscle cells (13).  
 
Group 2 PH 
Group 2 is PH developed due to left heart disease. The prevalence of this group 
is the highest of the 5 WHO classifications as heart failure is one of the largest public 
health emergencies with over 23 million cases worldwide (14). It is difficult to establish 
the exact number of these patients that develop PH as it is often a consequence of 
progression in heart failure. The pathophysiology of the development of Group 2 PH is 
unique in that it begins as a mechanical stress due to increased pulmonary venous 
pressures due to the left heart dysfunction (15). This stress then causes damage to the 
pulmonary vasculature and only then do I see similar remodeling and vasoconstrictions 
to other forms of PH and eventual right heart changes (16).  
 
Group 3 PH 
Group 3 PH is associated with chronic lung diseases such as IPF and COPD but 
it also a result of chronic hypoxia, such as that encountered in high altitude 
environments (1). Overall Group 3 PH is more common than Group 1 PH, true incidence 
though must be looked at in conjunction with the associated primary chronic lung 
disease (17). Diagnosis of increased pulmonary artery pressures in patients with chronic 
lung disease is difficult as right heart catheterization is quite invasive and 
echocardiography is not as sensitive even with recent advances (18).  The prevalence of 
IPF is estimate to be 14-43 per 100,000 while the prevalence of PH amongst IPF patients 
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is dependent upon the severity of IPF. In the early stages or when initially diagnosed, 
PH affects < 10% of IPF patients. However, as IPF advances, the incidence of PH 
increases markedly. One study of patients awaiting lung transplant, and thus in an 
advanced stage of IPF, reported prevalence of 32%. Subsequent studies have largely 
supported or increased this percentage to be between 32 and 50%. However, it is 
important to mention that the symptoms for PH and IPF are very similar (shortness of 
breath and exertional dyspnea) and as such it is conceivable for PH to be 
underdiagnosed in patients with IPF. Furthermore, typically the mPAP of patients with 
IPF is significantly lower than patients with Group 1 PH. Despite this, the presence of 
PH in IPF is strongly linked to the increased mortality and efforts aimed at treating PH 
in IPF may provide much needed therapies to diminish the mortality of IPF.  IPF is a 
disease for which there is no curative treatment outside of transplantation, thus out of 
proportion PH, which disqualifies patients from transplants, is a serious confounding 
factor (19). The treatment options seen in Group 1 PH have not proven to be successful 
in Group 3 PH or have had adverse clinical outcomes (20, 21). This and the strong 
mortality link make understanding the mechanism of PH development critical to 
treating patients with a diagnosis of chronic lung disease. 
COPD prevalence is much higher than IPF at 7.6% of the population (22). Similar 
to IPF the prevalence of PH associated with COPD is dependent on the severity of 
COPD. In early stage COPD as few as 10% of patients may have increased pulmonary 
pressures (18). In patients awaiting surgical intervention and thus having severe COPD 
the rates may be near 90% (23). Patients with PH associated with COPD have almost 
50% increase in 5-year mortality rate (24). Five-year survival rates for Group 3 PH after 
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initial diagnosis are 41.4% but the identity and severity of the underlying lung disease 
obviously has large impacts here (3). 
An additional chronic lung disease that is associated with PH is combined 
pulmonary fibrosis and emphysema (CPFE). This relatively recently defined disease has 
fibrotic deposition associated with emphysematic destruction of alveoli (25). Alone 
CPFE has a 5 year survival rate of 55% but when associated with PH 1 year survival rates 
may be as low as 60% (26). Additionally, up to 90% of CPFE patients will develop PH. 
As this disease has what on the surface appear to be countervailing mechanisms of 
fibrotic deposition and destruction of alveoli, it is important to discover the molecular 
mechanisms that can contribute to both events. While there have been multiple gene 
mutations associated with CPFE these mutations have not yet been shown to be 
widespread, as their discovery was part of familial cohorts or case studies (27). 
Unfortunately, treatment of CPFE or Group 3 PH overall, is limited to controlling 
symptoms and lung transplantation (28).  
A more distinct form of Group 3 PH is associated with hypoxia at high-altitude. 
This type of PH can both be acute and chronic (29). In acute high-altitude PH patients 
can develop increased pulmonary pressures very quickly due to an excessive 
vasoconstriction caused by hypoxia (30). In fact, acclimatization does not appear to 
reduce increases in pressure but does reduce symptoms, potentially by subtle 
remodeling of the vasculature to better protect from increased pressures (31). 
Additionally, changes seen in this group are reversible by returning to low altitudes. 
Chronic high-altitude pulmonary hypertension is a threat to the more than 140 million 
people living above 2,500 m elevation. It is estimated that in these populations 5-18% of 
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residents will develop high altitude PH (32).  Healthy residents at high altitude have 
thickened pulmonary artery walls that may form before birth (33, 34). This remodeling 
is not the key driver for this PH as even in chronic cases aberrant vasoconstriction 
appears to be the most important mechanism of increased pressure. Patient with this 
disease are encouraged to move to low altitude which will manage the disease but many 
pharmacological interventions have shown promise with none moving to widespread 
use. Most promising are experiments with fasudil as well as acetazolamide, a carbonic 
anhydrase inhibitor, which has several larger studies with excellent results (35, 36).  
 
Group 4 PH 
Group 4 PH is PH developed due to a chronic thromboembolic disease. Patients 
that develop a pulmonary embolism, especially those with coagulation disorders or 
autoimmune disease, are at risk though less than 4% of these patients will develop the 
chronic disease (37, 38). An unresolved pulmonary embolism causes occlusion of 
pulmonary vessels causing increased localized pressures and shear stress. This in turn 
results in remodeling of the affected vessels (38). As this is most often confined to one 
section of the lung, surgical intervention to remove the blocked vessel is often effective 
(39).  
 
Group 5 PH 
Group 5 PH is PH with unclear multifactorial mechanisms. This classification is 
a catchall for PH that is associated with disease states not incorporated in the other 
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groups (2). As this is a diverse group little research links the mechanism of this group. 
The most well described disease associate with Group 5 PH is sickle cell disease which 
can lead to PH due to left ventricle dysfunction or vascular stress caused by hemolysis, 
embolisms or hypoxia (40). 
Though the exact number of patients affected by all classifications of PH are hard 
to calculate, the patients impacted by these diseases have severely reduced quality of 
life and have much lower life expectancy. With the rise in cases of chronic lung disease 
in recent decades and the lack of treatment options, it is important to thoroughly 
understand the molecular and cellular mechanisms that underpin how PH develops. 
Only by this understanding can novel treatment options be explored. 
 
Disease Mechanism 
 The primary mechanisms involved in the increase of pulmonary vascular 
pressures in PH are increased vasoconstriction and sustained vascular remodeling. 
Many cell types have been shown to be involved in the development and progression of 
PH including pulmonary artery endothelial cells, fibroblasts, and immune cells such as 
macrophages. Vascular endothelial cells are the inner most cells of the pulmonary 
vasculature, as such they are often the first cells damaged by stress events that initiate 
remodeling seen in PH. Endothelial cells also have strong signaling connections with 
pulmonary artery smooth muscle cells (PASMCs) through endothelin-1 and nitric oxide 
signaling as well as many growth factors (41, 42). Vascular inflammation is a key 
characteristic of PH and as such macrophages have been implicated in multiple roles 
during the development of PH (43). Blocking macrophage activity or development has 
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shown efficacy in halting or reversing PH in some model (44, 45).  
PASMCs are very involved in both vasoconstriction and vascular remodeling. 
This makes PASMCs an exciting target for research hoping to understand the 
underlying molecular mechanisms that contribute to PH. While PASMCs of the 
proximal pulmonary arteries have a heterogeneous phenotype the cells of the distal 
pulmonary arteries, which are more involved in PH development, have a more uniform 
phenotype (46, 47). These PASMCs have a well differentiated phenotype that expresses 
many factors indicative of a contractile capacity and a low proliferative potential. These 
cells are key in modulating vascular tone that allows for control of pulmonary artery 
pressure and changes in flow rate seen during periods of activity (48).  In a healthy 
pulmonary artery, there are three regions when viewed cross-sectionally. The inner 
layer is the intima comprised of pulmonary artery endothelial cells. Next is the medial 
layer of PASMCs and finally the adventitial layer which signals the transition to other 
lung structures, is comprised of other cell types including fibroblasts.  In a PH artery, 
the intima may be infiltrated by smooth muscle cells, the medial smooth muscle cells 
will proliferate and hypertrophy while the adventitial layer will have increase in 
fibroblasts and macrophage infiltration (40). These changes contribute to the main 
pathological signs of PH, medial hypertrophy leading to reduced lumen in previously 
muscular arteries and increased abundance of muscular arteries due to muscularization 
of peripheral arteries and potentially plexiform lesions (1).  
 PASMCs undergo many phenotypic changes during the initiation and 
development of PH. Early in the development it has been shown by many experimental 
models that there is an increase in proliferation. This was first seen in the rat hypoxia 
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model in which there was a small amount of medial PASMC proliferation increase and 
confirmed in the monocrotaline rat model where there was observed a more robust 
increase in proliferation (49, 50). The hypoxia model of rat pulmonary hypertension 
treats the rats with 14 days of hypobaric hypoxia (49). In the monocrotaline model rats 
are treated with a single dose of monocrotaline which causes pneumotoxicity. After 14 
days the pulmonary arteries are very inflamed and PASMCs are contracted and by day 
22 there are right ventricle dysfunctions (51). Of interest is that despite the differences 
in these two models in showing a change in medial PASMC proliferation both models 
show a very significant increase in the number of muscularized vessels indicating not 
just a concentric increase in PASMC but also spreading of these cells to more distal 
portions of the arteries (52). As more models of PH have been developed, these changes 
in proliferation have been more precisely studied. More recent studies have confirmed 
the early increase in proliferation seen but indicate that this proliferative capacity 
decreases as the model continues and the cells potentially progress into a second 
phenotype change (53). This has been observed in the mouse Schistosomiasis model 
and in one of the more utilized models of PAH, the hypoxia-sugen rat model (53, 54).  
The Schistosomiasis model involves inoculating mice with Schistosoma mansoni and 
then a second hit with i.v. administration of S. mansoni eggs. Seven days after 
administration of the eggs, PH develops in an IL-13 dependent mechanism (54). The 
hypoxia-sugen model treats mice with 28 days of 10% oxygen and four treatments with 
a vascular endothelial growth factor inhibitor leads to increased pulmonary pressures 
and remodeling (55). PASMC proliferation provides for the medial thickening seen in 
the development of PH and provides an increased pool of PASMCs to participate in the 
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other abnormal phenotypes that are introduced below. 
 Another phenotypic change seen in PASMCs during the development of PH is 
an increase in cellular tone. During exercise the cardiac output of the right ventricle will 
increase to provide for more oxygen delivery (56). To minimize the increase in 
pulmonary artery pressure due to this increase in right heart effort the pulmonary 
arteries relax, allowing for a reduction in pulmonary vascular resistance. In fact, in a 
multi-study analysis it was seen that the slope of the relationship between mPAP and 
cardiac output in an individual can vary by as much as 6 fold when a stable linear 
relationship would be seen in a non-contractile system (57). If this relaxation does not 
occur then pulmonary pressures will increase as seen in PH. As with many other key 
cellular signaling events, Ca2+ activated response controls the contractility of PASMCs 
(58). Since Ca2+ signaling has other outputs, many studies have worked to understand 
the signaling necessary for the contractile response in PASMCs.  A key phosphorylation 
event is the phosphorylation of myosin regulatory light chain (59). The levels of this 
phosphorylation are controlled by the interplay of calcium-calmodulin dependent 
myosin light chain kinase and the MLC phosphatase (60). PASMC contractility is not 
controlled by a change in Ca2+ but by a calcium sensitization caused by the Rho-kinase 
(ROCK) dependent phosphorylation of myosin targeting phosphatase subunit (60). 
ROCK is previously activated by Ras-homology A(Rho) in its GTP bound state (60). This 
sensitization ends when regulatory proteins cause RhoA to cleave GTP (61).  These 
proteins and the nucleotide exchange factors are under tight control, allowing for 
multiple upstream pathways to control PASMC contractility (62). As there are many 
signaling pathways controlling PASMC contractility it is of no surprise that in PH many 
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pathways and signaling mechanisms can lead to increased vascular tone.  One of the 
mediators involved is endothelin. Endothelin-1 is released from pulmonary artery 
endothelial cells due to stress and signals through the Endothelin receptor B (63). This 
signaling leads to Ca++ dependent signaling changes through IP3 (64). This complex 
control of contractile response in PASMCs allows for fine tuning of the vascular 
resistance in healthy individuals and maintains a suitable pulmonary artery pressure 
but allows for changes in signaling in a disparate set of pathways to abnormally control 
this contraction in the development of PH. 
An additional change seen in PASMCs is an increase in the production of 
extracellular matrix (ECM). The ECM is a combination of proteins and polysaccharides 
surrounding the cells of every tissue. The exact make up of ECM in each tissue varies 
and ECM is dynamically produced and degraded (65). The ECM does not only provide 
a structural lattice for cellular components of tissues but also plays an important role in 
signaling many cellular activities including proliferation, migration and cellular 
distribution through interactions with many signals including growth factors (66). The 
main protein component of all tissue and of the ECM is collagen, a protein whose many 
functions and interactions are only rivaled by the many classifications and variants 
expressed. Collagen provides tensile strength, cell interactions, migration and tissue 
polarization cues. A second ECM protein is elastin, a highly crosslinked protein that 
helps provide stretch and recoil to tissues. The third major protein in ECM is, in concert 
with collage, which is very important in the development and presentation of many 
chronic lung diseases including PH and IPF is fibronectin (FN). FN has been implicated 
in a feedback loop that keeps PASMCs in a synthetic phenotype with increased 
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proliferation (67, 68). The other molecule type that composes a large portion of the 
ECM are glycosaminoglycans. These polysaccharides are usually found covalently 
bound to a variety of ECM proteins and provide interactions and help provide a strong 
and hydrated matrix (69). These proteoglycans often are helper proteins in cell surface 
receptors (70). One exception to extracellular glycosaminoglycans being covalently 
bound to proteins is hyaluronan (HA).  This molecule instead binds to many ECM 
proteins and cell surface receptors such as CD44 through specific binding motifs called 
Link domains, though as the catalogue of HA binding proteins expands some lack this 
domain (71). This molecule will be further introduced later in the thesis. During the 
development of PH, a population of PASMCs may switch into a synthetic phenotype 
which can deposit these ECM components. This deposition allows for multiple effects. 
The modified ECM can feedback into the PASMCs maintaining an abnormal phenotype 
(67). The new ECM can provide a foundation for cell adhesion and immune cell 
infiltration into the vasculature (72). Finally, the excessive ECM can cause mechanical 
stiffening to the pulmonary vasculature and physical block to gas exchange (73). 
Together these PASMC dependent ECM changes contribute to many of the other 
phenotypic changes seen in the development of PH and provide an important research 
subject.  
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Figure 1 Vascular Remodeling 
Adapted from Pulmonary Hypertension Associated with Idiopathic Pulmonary 
Fibrosis: Collum SD, Amione-Guerra J, Cruz-Solbes AS, DiFrancesco A, Hernandez 
AM, Hanmandlu A, Youker K, Guha A, Karmouty-Quintana H. Pulmonary 
Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future 
Perspectives. Can Respir J 2017 
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Chapter 2: Background  
 
RNA Processing  
 Transcription of protein coding mRNAs by RNA polymerase II is the first step in 
turning genetic information in the DNA of cells into molecules that can maintain the 
homeostasis of the cells, decide cell fate, and provide the functional capacity for this 
fate. It is not surprising then that transcription is a process involving many steps each 
of which is complex and must be tightly regulated. To properly discuss the final step in 
transcription, cleavage and polyadenylation, it is useful to briefly discuss the 
transcriptional processes that precedes it. The basic structure of a viable, stable and 
translatable mRNA is to contain a 5’ m7G cap, a 5’ untranslated region (UTR), the coding 
sequences containing a start codon and a final stop codon, a 3’ UTR and finally a poly(A) 
tail of many adenosine monophosphates.   
The first step of transcription is initiation. During this process five general 
transcription factors assemble with RNA pol II to form the preinitiation complex. This 
complex recognizes the DNA regions that most eukaryotic RNA pol II genes contain 
called the TATA-box and the TFIIB recognition element. These sites are about 30 bases 
upstream of the transcription start site and allow for proper positioning of the 
transcription complex. This site recognition can be modified by transcription cofactors 
and enhancer regions and the proteins that bind them called activators and repressors. 
Control of transcription initiation is provided by large protein complexes interacting 
with each other and DNA over 100 Mb away (74). After initiation of a stable complex 
the RNA pol II begins elongation adding nucleotides sequentially to the 3’ of the nascent 
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mRNA. After 25-30 nucleotides the capping enzyme is recruited by a phosphorylated 
serine on the RNA pol II and carries out three enzymatic steps to cap the mRNA. The 
final step in this cap addition, the methylation by RNA guanine-N7 MTase can be also 
controlled in a cell cycle manner by CDK1-cyclin BI (75). Another co-transcriptional 
mRNA processing event that begins during elongation is splicing. Similar to the 
recruitment of the capping enzyme by RNA pol II the spliceosome, a large complex of 
proteins and small nuclear ribonucleoproteins, is recruited by a C-terminal domain 
phosphorylation (76, 77). The spliceosome then recognizes splice sites within the pre-
mRNA and removes intervening sequences that do not form a portion of the mature 
RNA (78). Splicing was discovered to not be a constitutive process but to have many 
variations and controls. In fact alternative splicing has helped to explain the disconnect 
between the number of putative genes and mature proteins that are produced, as it has 
been discovered that at least 70% of human genes undergo alternative splicing in tissue 
or developmental regulated manner (79). It is also calculated that up to 60% of human 
heritable diseases involve a splicing change due to mutation (80). Splicing provides yet 
another process to control mRNA processing. The final step in transcription and 
maturation of RNA pol II mRNAs is cleavage and polyadenylation. This process involves 
the recognition and enzymatic cleavage of a cleavage site and then the addition of a 
poly(A) tail, this is known as cleavage and polyadenylation.  
 
Cleavage and polyadenylation 
 
 Cleavage and polyadenylation is carried out at a location of the pre-mRNA 
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defined by a set of sequence signals of which are relatively well conserved with potential 
activity with major mutations and a set of more diffuse and weaker signals that stabilize 
the more conserved signals (81). These signals do vary by species so here is described 
the signal elements for mammals. The first and strongest signal is a hexamer sequence 
AAUAAA just upstream of the cleavage site. Other similar hexamers have much reduced 
processing activity while AUUAAA and AGUAAA retain 80% and 30% respectively (82).  
The first synthetic poly(A) site consisted of this hexamer and a U/GU rich sequence 22 
nucleotides downstream (83). Besides these strong signals there is an U-rich region 
within 100 nucleotides upstream and downstream as well as potential G-rich elements 
more than 30 nucleotides downstream (84). The RNA sequence UGUAN can also act as 
a strong promotor of cleavage and polyadenylation and is often found upstream of the 
PAS (85). Cleavage and polyadenylation is carried out by a protein complex that is 
known to have greater than 80 associated factors. Of these associated factors 19 proteins 
make up the core of the machinery (86). The cleavage and polyadenylation specificity 
factor (CPSF) is a sub-complex made of six required proteins; WDR33, CPSF30, CPSF160, 
hFip1, CPSF100, and CPSF73. WDR33 is the protein that binds the AAUAAA hexamer 
while CPSF30 and CPSF160 assist in this recognition and binding (87, 88). While both 
CPSF100 and CPSF73 contain metallo-β-lactamase and 𝛽-CASP domains it is CPSF73 
that cleaves pre-mRNAs (89). The CstF complex is a trimeric complex that recognizes 
downstream elements in the PAS. It consists of CstF64, CstF77, and CstF50 (90). 
Together these proteins recognize U/GU rich regions as well as modulating some 
protein interactions outside the cleavage and polyadenylation machinery (91, 92). 
Symplekin is a protein that acts as a scaffold for the arrangement of several of the 
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subcomplexs of the larger cleavage and polyadenylation complex (93). The mammalian 
cleavage factor I is made of 3 proteins, Nudix Hydrolase 21 (NUDT21), CPSF6 with two 
splicing isoforms, and CPSF7 (94). NUDT21 binds the UGUAN while forming a dimer 
with itself and potentially a tetramer with a dimer of one of its complex partners (94). 
When in this tetramer with CPSF6 it is known that this binding to RNA can cause a 
looping which is theorized to be important in recognition of a proper cleavage and 
polyadenylation site and alternative polyadenylation (APA) (95, 96). The mammalian 
cleavage factor II complex contains up to 20 proteins but only (Cleavage and 
Polyadenylation Factor Subunit 1 (Clp1) and Pcf11 have been well characterized. Clp1 
appears to assist in the assembly of CFIm and CPSF while Pcf11 is essential for 
degradation of the remaining nascent RNA after cleavage (97, 98). The final proteins 
considered part of the core cleavage and polyadenylation machinery are Poly(A) 
Polymerase Alpha (PAP) and Poly(A) Binding Protein Nuclear 1 (PAPBN1) which add 
the poly(A) tail. PAP catalyzes the reaction adding adenosines in a template-
independent manner while PABPN1 binds the tail as it is added and increases the 
catalytic rate of PAP (99, 100). Additionally the C-terminal domain of the RNA pol II is 
again key in recruiting the factors discussed here (101).  
 
Alternative Polyadenylation 
 Alternative polyadenylation is a process in which an pre-mRNA with multiple 
poly(A) signals may use a non-canonical site. While this mechanism of regulating 
mRNAs was first proposed and discovered in a few specific cases in the 1980s, amongst 
others the IgM heavy chain and dihydrofolate reductase, it was not until more 
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sophisticated techniques in the modulation of protein levels and RNA quantification 
were developed that the true scope of this process could be recognized (102, 103). With 
the advent of next generation RNA sequencing technology the ability to identify APA 
events as a result of many diseases or manipulated protein levels showed that at least 
69.1% of human genes have multiple poly(A) sites (104). There are four basic types of 
APA as grouped by the location of the non-canonical poly(A) site. The first and most 
easy to visualize is tandem 3’UTR APA which occurs when there are additional poly(A) 
sites within a single 3’UTR. Tandem 3’UTR APA is the only type which generates an 
identical protein coding sequence and thus this form of APA has a more difficult effect 
to study (105).  Alternative terminal exon APA creates a new terminal exon and 3’UTR 
while intronic APA is similar but also retains a canonically spliced intron (105). Finally 
is internal exon APA which maintains the typical splicing pattern but cleavage 
recognizes a typically ignored sequence within one exon which is the most rare of APA 
events (106).  The rest of this thesis will focus on Tandem 3’UTR APA as while this type 
does not affect the coding sequences changes in the 3’UTR length can affect the stability, 
translation efficiency, and cellular localization of mRNAs through loss of miRNA 
binding sites and RNA binding protein sites (Figure 2). These changes will affect 
signaling, disease processes, and development. 
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Regulation of APA 
As can be seen by the large number of complexes that interact during 
transcription and cleavage and polyadenylation, it is not surprising that many factors 
can modulate the occurrence of APA events. APA can be controlled by simple kinetics 
of transcription where pausing increases nearby poly(A) site usage (107). Additionally 
the efficient recruitment of cleavage and polyadenylation complex by RNA pol II and 
transcriptional activating proteins early in transcription can influence poly(A) site usage 
(85). Many RNA binding proteins also regulate APA events. Two examples are SR 
proteins Serine and Arginine Rich Splicing Factor 3 (SRSF3) and Serine and Arginine 
Rich Splicing Factor 7(SRSF7) were first discovered to regulate splicing but have also 
been observed to lengthen and shorten 3’UTRs of mouse cells (108). Splicing is also 
linked to the control of APA. To avoid premature cleavage and polyadenylation U1 
snRNP inhibits poly(A) site usage in introns in a process termed telescripting (109). 
Telescripting may also play a role in APA of genes during periods of transcriptional 
upregulation (110). Of great interest is the effect of the cleavage and polyadenylation 
Figure 2 3’UTR APA 
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complex levels on APA. Changes in the levels of each of the core components appear to 
have different effects. Increases in CSTF64 was seen to increase CSTF complex and 
increased the usage of a proximal poly(A) while downregulation of expression leads to 
global lengthening in HeLa cells (102, 111). This suggests that the CstF complex may 
follow this trend. 
In stark contrast to APA changes seen by modulating levels of CSTF64, down 
regulation of CFIm complex members leads to a strong shortening on a global level (112). 
Of note the most robust 3’UTR shortening seen is with the knockdown of NUDT21 (113).  
This change has now been seen to play a role in multiple disease states. 
 
NUDT21 Regulated APA and Disease 
 As the role of CFIm complex members in controlling APA was being discovered, 
multiple diseases were found in which levels of NUDT21 were modified as was global 
poly(A) site usage. One of the first studies that linked NUDT21 to a disease was by 
Masamha et al. which described the role of CFIm25 (NUDT21) in glioblastoma tumor 
suppression (113).  In this paper it was described that in cell culture human glioblastoma 
cells had lower levels of NUDT21 and that this directly contributed to a more 
proliferative phenotype as well as a more aggressive tumor in a xenograft mouse tumor 
model. This study also identified 1450 genes that underwent APA with NUDT21 
knockdown. An additional disease in which NUDT21 was found to play a role was 
pulmonary fibrosis (114). In this study by Weng et al. reduced NUDT21 induces APA in 
many genes in lung fibroblast and leads to worsening fibrosis in the bleomycin mouse 
model. Additionally, a knockout of NUDT21 contributed to increased expression of 
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collagen fibronectin and TGF-βR1. APA induced by NUDT21 level changes has been 
implemented in many changes in other cancers including hepatocellular carcinoma in 
which cellular migration and invasion are increased with depleted level as well as in 
osteosarcoma in which similar changes are seen (115, 116). NUDT21 copy number 
changes also play a role in the neuropsychiatric disease Rett syndrome by controlling 
levels of the protein MeCP2 (117). 
NUDT21 regulated APA has been shown to play a role in several diseases 
including the chronic lung disease IPF. This APA is also associated with changes in cell 
proliferation and cell migration as seen in the study on glioblastoma. These changes in 
cell phenotype may resemble changes seen during the initiation and development of 
PH and provide a unique opportunity to discover a mechanism of disease progression. 
This thesiswill describe a role for NUDT21 in PH.  
 
Hyaluronan  
Hyaluronan is a non-protein component of the ECM with a repeating 
disaccharide structure of N-acetyl-glucosamine and glucuronic acid. HA is produced in 
mammals by three hyaluronan synthases (HAS), 1-3. These synthases produce HA in a 
broad range of molecular weights, generally above 2x105 Da with HAS2 generally 
producing at molecular weights an order of magnitude higher than the other enzymes. 
HAS2 is an essential gene for mouse embryonic development but a double knockout of 
the other enzymes is viable with abnormal wound healing. Offsetting these HA 
producing enzymes are four hyaluronidase isoforms (Hyal1-4). Of these, Hyal2 has 
shown to be the most necessary with deficient mice accumulating HA in the heart and 
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developing severe cardiac phenotypes (118). Hyal1 and Hyal3 deficient mice show minor 
changes in skin dendritic cells and alveolar structure respectively (119). While some of 
the effects may seem minor, Hyal are quite important as in humans one third total HA 
is turned over each day, either absorbed by cells by endocytosis or cleared from the 
blood by liver endothelial cells (120). HA can also be degraded in an uncontrolled 
manner by reactive oxygen species (121). As with other ECM components, HA is bound 
by many proteins including proteoglycans. This forms a complex mesh that may play a 
role in organizing activities and signaling in the ECM in a structure referred to as 
pericellular matrix or glycocalyx (122). HA conformational changes by TSG-6 through 
heavy chain transfer from inter-α-inhibitor, as well as binding to versican and aggrecan 
may modify this structure (123). This higher order structure also plays a role in 
development and in cancer cell survival (124, 125). One of the most described HA 
receptors is CD44. This receptor also binds other ECM components such as collagen 
and fibronectin but has HA dependent activity that results in cell motility and 
inflammation changes as well as HA clearance (126).  Another important receptor of HA 
is Receptor for HA-Mediated Motility (RHAMM) which has been linked to proliferative 
responses and motility in smooth muscle cells as well as participating in acute lung 
injury (127, 128). Additionally Hyaluronic Acid Receptor for Endocytosis (HARE) and 
Layilin act as HA receptors in certain cell types where they are associated with 
endocytosis activation and epithelial barrier function respectively (129-131). HA plays a 
role in many biological functions by interacting with special domains in cell surface 
receptors and other ECM components. These functions include cell fate and organ 
development, injury response, cell migration including cancer progression, as well as 
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playing an important role in maintaining a well hydrated matrix (120). However, 
depending on the context HA seems to have contradicting effects. One of these 
contradicting effects in the seeming opposing forces of high molecular weight(HMW) 
HA in an anti-inflammatory activity and low molecular weight(LMW) HA in a pro-
inflammatory activity (132). While it is suggested that receptor interaction changes due 
to molecular weight could play a role here, it is also indicated that inter-α-inhibitor 
modification of HMW HA is reversible while LMW modification is not reversible (133).  
This is important because inter-α-inhibitor modification greatly increases inflammatory 
cell recruitment by HA (134). Early studies on the effect of HA on proliferation showed 
a marked decrease in cellular proliferation when treated with HA (135). As studies began 
to look at more cell types and cells in different conditions it was found that HA can 
robustly increase proliferations in other circumstances (136, 137).  While it has been 
shown that this is at least partially due to differences in molecular weight, it is also 
linked to differences in receptor recognition and downstream signaling (136). 
Additionally, LMW HA is strongly linked to angiogenesis through the ephrin receptor 
A2 (138). Refer to (Figure 3) for an illustration of the HA pathway. 
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 Figure 3 Hyaluronan Enzymes and Interactions  
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Hyaluronan and Disease  
 Altered Hyaluronan production and degradation have been associated with 
various diseases. Extensive research has shown that HA and HA related enzymes play 
important roles in cancer, especially in cell survival, proliferation, and metastasis (120). 
Colon and breast cancer lines express high levels of Hyal1 and Hyal2 as well as CD44 
and depletion of HAS2 resulted in reduced cancer phenotypes (139-141). HA levels in the 
serum of diabetic patients are raised and adipose CD44 signaling has also been 
associated with this disease (142, 143). HA overexpression in mouse models of 
atherosclerosis leads to increased plaque formation, potentially through CD44 signaling 
in macrophages and smooth muscle cells (144, 145).  
HA has been found to play an important role in multiple lung diseases. As HA 
regulates inflammation, it is not surprising that HAS2 mutations have been found to 
be associated with asthma (146). Additionally, HA is elevated in asthma patients and 
increased HA is related to worsened symptoms (147).  Cells isolated from patients have 
elevated HAS2 levels and produce lower molecular weight HA than cells from healthy 
patients (148). HA level changes are associated with COPD, where augmented levels of 
HA and HAS2 expression has been reported (149). Some groups looking at specific 
subsets of COPD patients or looking specifically at airway smooth muscle cells have 
reported reduced levels of HA, HAS1 and HAS2 (150, 151).  Increased HA deposition is 
also associated with IPF. Patients with IPF have increased HA in the bronchoalveolar 
lavage fluid compared to healthy individuals (152). Additionally, fibroblast cultured 
from these patients show increased HA deposition with increased HAS2 expression 
(153). The bleomycin mouse model also shows increase HA deposition while HAS2 
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knockout mice show improvements in fibrosis (153). Exogenous hyaluronidase 
treatment in this model has been shown to attenuate fibrosis (154). Of note, increased 
HA levels have been observed in patients with Group 1 PH, associated with increased 
HAS1 and HYAL1 expression (155). Excessive HA has also been observed in the plasma 
of patients with PH associated with congestive heart failure and COPD (156). This 
association has also been observed in the rat monocrotaline model as well as the 
adenosine deaminase (ADA) deficient mouse model of lung injury (157, 158). This 
evidence along with the role of HA in eliciting cellular response similar to those seen 
in PASMCs in PH indicates that the role of HA in PH should be further investigated. 
This thesis will untangle some of this pathway in PH. 
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Dissertation Overview 
PH is a chronic lung disorder with increasing prevalence which has a great 
impact on the quality of life and mortality of hundreds of thousands each year (1, 5). PH 
patients typically have 5 year survival rates below 70% and PH is a common and 
significant comorbidity with other chronic lung disease, serving as one of the most 
significant indicators of poor prognosis (3). One of the patient groups greatly affected 
by PH is those that also present with chronic lung diseases such as IPF or COPD (1). 
Within this cohort of patients with chronic lung diseases, patients presenting with a 
rare presentation of combined pulmonary fibrosis and emphysema (CPFE) have a 
higher prevalence of PH (19). Up to 90% of CPFE patients develop PH and this diagnosis 
reduces the survival rate from 55% for 5-year to 1-year survival rates of only 60% (159).   
Understanding the molecular and cellular mechanism that give rise to these diseases is 
important as few therapies exist and no curative treatments are available outside of lung 
transplantation (7).  This thesis explores two such mechanisms; NUDT21 induced APA 
and increased HA deposition.  
Previous studies have indicated that APA is an important regulatory mechanism 
during the transcription of mRNAs (105). APA events induced by reduced level of 
NUDT21 have been implicated in cancers and IPF (113-115). In some diseases NUDT21 
depletion correlated with increased proliferation and changes in cell migration similar 
to those seen in the PASMCs during PH progression (113). The role of NUDT21 in 
controlling the phenotype of PASMCs has not been described and no link to PH has yet 
been proven. 
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HA is a glycosaminoglycan that makes up a large portion of the lung ECM. This 
molecule is an important structural component linking many proteins together and 
often controlling cell adhesion, while also being an important signaling molecule 
binding several receptors including CD44 and RHAMM in vascular smooth muscle (127, 
160). In disease states such as IPF, HA synthesis and degradation are dysregulated and 
increased levels of HA have been measured in patients and animal models of PH and 
secondary to fibrosis and other lung injuries (153). A complete understanding of the role 
of HA and the many enzymes involved in its production, degradation, and signaling in 
PH has not been gained. This project hypothesizes that NUDT21 depletion and 
aberrant HA accumulation are important drivers of PH through changes in 
PASMC phenotype  
 
Specific Aim 1: Determine the role of NUDT21 depletion and subsequent APA in 
the development of PH. 
Patient samples and healthy controls were measured for NUDT21 and other 
CFIm complex member levels by immunohistochemistry staining and western blotting 
showing decreased levels. Using the hypoxia-sugen mouse model and the NUDT21F/-
Tagln-CreKI mouse line it was shown that depletion of NUDT21 contributes to 
worsened PH symptoms. In cell culture of healthy and PH PASMCs it was shown that 
low NUDT21 levels are associated with increased proliferation and reduced migration 
in a Boyden chamber assay. The results of this aim are presented in Chapter 3. 
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Specific Aim 2: Determine the role of hyaluronan in the development of 
pulmonary hypertension. 
I show that 4-Methylumbelliferone (4MU), a drug that inhibits HA production, 
is sufficient to reduce PH symptoms in the hypoxia-sugen model of PH and bleomycin 
model of lung fibrosis and PH. It was also shown that deletion of HAS2 from the 
PASMCs of mice in the hypoxia-sugen model reduces PH.  HA, HAS1 and HAS2 levels 
were seen to be associated with PH by western blot and RT-PCR. These results were 
recapitulated in the bleomycin model of lung fibrosis and PH. PASMCs treated with 
small fragments of HA present with increase proliferation, migration and stiffness, all 
hallmarks associated with PH. These results are presented in Chapter 4.  
 
Specific Aim 3: Determine the role of HA in PH associated with CPFE. 
CPFE is complicated disease in which PH plays an important and deadly role. 
Patient samples of this disease show an increase in HAS3 expression and HA 
accumulation. A novel model of CPFE, adenosine deaminase (ADA-/-) deficient mice, 
confirmed these findings. Here I show that 4-MU reduced HA levels in the ADA-/- mouse 
model of PH. These findings were associated with a reduction in fibrotic deposition and 
PH, though no changes in airspace enlargement were seen. As the ADA-/- model 
recapitulates adenosine accumulation and signaling seen in CPFE patients, I showed 
that HAS2 and HAS3 are upregulated in an adenosine A2B receptor dependent manner 
in vitro. The results of this aim are presented in Chapter 5.  
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Identifying novel mechanisms that contribute to the development and 
progression of PH will lead to increased understanding of the pathogenesis of disease 
and eventually newly targeted therapies for the treatment of PH. The pathways 
described here are exciting new mechanisms that control the phenotype of PASMC and 
may be directly responsible for a portion of the vascular remodeling seen in PH as well 
as one of the first mechanisms described for the progression of CPFE.  
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Chapter 3: Loss of NUDT21 links APA with PH 
 
Introduction 
The vascular changes associated with PH include aberrant proliferation, cell 
growth and abnormal vasoconstriction and the development of complex vascular 
lesions (161). These changes in cell phenotype happen in several cell types but here I will 
focus on PASMCs as they form the large medial section of pulmonary arteries and can 
provide multiple mechanisms of vascular changes (162). Understanding the molecular 
pathways that lead to changes in PASMC phenotype is important in understanding the 
initiation and development of this disease. As APA has been recently described as a 
driver of multiple disease states, most provocatively in cancer and IPF, I hypothesize 
that NUDT21 loss and resulting APA may contribute the the development if PH by 
altering the PASMC phenotype (114, 163). 
The addition of poly(A) tails is a key process in the maturation of mRNA. An 
mRNA containing multiple polyadenylation sites in the 3’UTR may undergo a process 
known as 3’ UTR APA, in which the non-canonical polyadenylation site is used, leading 
to an alternate transcript (164). As these alternate polyadenylation sites often occur 
early in the 3’UTR a hallmark of this APA is 3’UTR shortening that leads to loss of 
binding sites for regulatory elements such as miRs allowing transcripts to escape mRNA 
regulation resulting in heightened levels of affected transcripts as well as allowing for 
changes is translation efficiency(112). Depletion of NUDT21, a RNA binding protein in 
the CFIm complex, is an important driver of 3’UTR APA (113, 165). This type of APA has 
been found to drive cell proliferation and invasion in cancer (113). While NUDT21 
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depletion can cause a few examples of other types of APA introduced in Chapter 2, this 
research will focus on 3’UTR APA (112). As many of the hallmarks of cancer, including; 
sustained proliferation, resistance to cell death, angiogenesis, and invasion, are 
recapitulated in the cells of patients with PH, especially PAH, I focused on the role of 
NUDT21 driven APA to control the phenotype of PASMCs and contribute to PH (166).  
My results reveal that NUDT21 is depleted in isolated PASMCs of patients with 
PH, both Group 1 and IPF + PH. This depletion was also recapitulated in a model of 
Group 1 PH, the hypoxia-sugen mouse. Additionally, mice with heterozygous removal 
of NUDT21 in PASMCs had increased PH symptoms over control mice. I also report a 
phenotypic change in human PASMCS with depletion of NUDT21 associated with an 
induction of proliferation and reduced migratory capacity. I also report several 
pathways which are enriched in APA events after NUDT21 depletion, including a 
shortening of the HAS2 gene and concomitant increases in HAS2 mRNA levels. These 
results show evidence for a novel role for NUDT21 regulated APA to control cell 
phenotype and contribute to disease progression in PH.  
 
Results 
NUDT21 is depleted in patients with Group 1 or Group 3 PH 
I first stained lung sections from healthy donors and patients diagnosed with 
PAH or IPF + PH for αSMA and NUDT21 expression. Serial sections were stained for 
NUDT21 and αSMA or DAPI and αSMA. I then quantified the cells that were αSMA 
positive with either NUDT21 staining or DAPI positive nuclei. This showed that patients 
with PAH or IPF + PH have reduced nuclear NUDT21 in remodeled vessels compared to 
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healthy vessels (Figure 4A-B). I then used flash frozen tissue samples to measure levels 
of CFIm complex members in the pulmonary artery of patients with PAH compared to 
control by western blot. Here I see a depletion in the level of NUDT21, CFIm59, and 
CFIm68 (Figure 4C-D). CPSF73 is an important part of the cleavage and polyadenylation 
machinery but is not a part of the CFIm complex and also does not change in level in 
PAH samples (Figure 4C-D). Subsequently, I performed a western blot on samples from 
healthy pulmonary arteries, arteries from lungs with IPF and arteries from lungs with 
IPF + PH. Interestingly here, I only saw a change in NUDT21 in the IPF and IPF + PH 
with no further depletion between IPF and IPF + PH. Meanwhile, CFIm59, CFIm68, and 
CPSF73 have no significant change (Figure 4E-F). Taken together this suggests that 
NUDT21 depletion is associated with PH. 
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Sequential lung sections double stained for α-smooth muscle actin (α-SMA; red signals) 
and NUDT21 (brown signals) from normal lungs (left) or patients with PAH (middle) or 
IPF + PH (right) (A). Quantification of NUDT21 positive nuclei in α-SMA positive cells 
and sequentially stained DAPI (ratio NUDT21 positive nuclei to DAPI) (B). 
Immunoblots for NUDT21, CFIm59, CFIm68, CPSF73 and GAPDH from Normal and 
PAH pulmonary arteries (C). Densitometries from C normalized to GAPDH(D). 
Immunoblots for NUDT21, CFIm59, CFIm68, CPSF73 and GAPDH in Normal and IPF 
and IPF + PH pulmonary arteries (E). Densitometries from E normalized to GAPDH(F). 
The N used for panel B 13 (Normal); 12 (PAH); 10 (IPF+PH). Data are shown as mean ± 
SD.* P ≤ 0.05  
Figure 4 NUDT21 depletion in PH. 
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Right Ventricle Systolic Pressure (RVSP) (A); Left Ventricle Systolic Pressure (LVSP)(B); 
Fulton index determined from measuring dry weights of RV and LV + septum (C). 
Immunoblot for NUDT21, CFIm68 and βactin (D). Densitometries of D normalized to 
βactin (E).  The N number used for these studies are 6 (Normoxia); 8 (HX-SU). 
Significance level * P ≤ 0.05  
Figure 5 Hypoxia-sugen model of PH shows reduced pulmonary artery NUDT21. 
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NUDT21 in the hypoxia-sugen model of PH 
I next wanted to verify that the depletion of NUDT21 seen in patient samples is 
recapitulated in a model of PH. In this experiment I used the hypoxia-sugen mouse 
model. Here mice of ~8 weeks are exposed to hypoxic condition of 10% O2 for 28 days. 
To further the model and prevent vascularization the mice are also treated weekly with 
20mg/kg of Sugen 5416, IP a vascular endothelial growth factor receptor antagonist.  At 
day 28 hemodynamics of the mice are measured and the mice are sacrifice to obtain 
samples. These mice have a significant rise in Right Ventricle Systolic Pressure (RVSP), 
a measure similar to mPAP of patients (Figure 5A). The Left Ventricle Systolic Pressure 
(LVSP) is not elevated in this model indicating no change in systemic blood pressure. 
These mice also have significant Right Ventricle Hypertrophy (RVH) (Figure 5C). My 
study showed that NUDT21 is depleted in the isolated pulmonary artery of these mice 
(Figure 5D-E). I also see depletion of CFIm complex member CFIm68 (Figure 5D-E). 
This indicates that this model is relevant for studying NUDT21 induced APA and PH. 
 
NUDT21 deficient mice are more susceptible to PH 
The Cre-Lox system is a very powerful tool for the genetic manipulation of mice. 
I acquired the NUDT21-Flox mouse line and crossed it with the Tagln-CreKI mouse line 
(114, 167). The Tagln-CreKI expresses cre recombinase from a knock in transgene at the 
transgelin gene locus. This allows for recombination of loxp sites that were introduced 
surrounding several exons of the NUDT21 gene in the NUDT21-Flox line. This allows for 
the specific deletion of NUDT21 from vascular smooth muscle cells. Unfortunately, the 
homozygous NUDT21-Flox Tagln-CreKI animals are embryonic lethal so I continued 
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with only a heterozygous knock out. In addition, there are no available mice with 
inducible expression of Cre in vascular smooth muscle cells. I then exposed these 
animals to the hypoxia-sugen model and measured hemodynamics and NUDT21 
expression. I show that even in normoxic conditions NUDT21 heterozygous KO is 
sufficient to increase the RVSP significantly, but when exposed to hypoxia-sugen these 
mice develop an augmented increase in RVSP (Figure 6A). Hypoxia in control mice was 
able to reduce NUDT21 levels by nearly half, a similar level to the heterozygous KO mice 
in normoxic conditions (Figure 6C-D). This data suggests that NUDT21 is a causative 
agent in PH and that understanding the mechanism is important for understanding this 
disease. 
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TaglnCre Normoxia, Nudt21f/+ TaglnCre Normoxia, TaglnCre Hypoxia-sugen, Nudt21f/+ 
TaglnCre Hypoxia-sugen. RVSP (A); LVSP(B); Immunoblot for NUDT21 and 
GAPDH(C). Densitometries of C normalized to GAPDH (D). The N used for these 
studies are 5 (TaglnCre Normoxia); 10 (Nudt21f/+ TaglnCre Normoxia); 10 (TaglnCre 
Hypoxia-sugen); 9 (Nudt21f/+ TaglnCre Hypoxia-sugen) for panel A and 5 (TaglnCre 
Normoxia); 5 (Nudt21f/+ TaglnCre Normoxia); 7 (TaglnCre Hypoxia-sugen); 8 (Nudt21f/+ 
TaglnCre Hypoxia-sugen) for B. Variations in N are due to violation of a predetermined 
criteria: heart rate below 250 BPM at the time of LVSP. 
  
Figure 6 PASMC KO of NUDT21 worsens pulmonary hypertension. 
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NUDT21 controls the phenotype of PASMCs 
To determine the role that NUDT21 played in controlling PASMC phenotype, I 
harvested and cultured these cells from healthy donors and lungs from patients with 
PAH. I first measured the proliferative capacity of the healthy PASMCs by starving them 
for 72 hours followed by treatment with control or NUDT21 siRNA. I then stimulated 
the cells with vehicle or 25µM PDGF for 48 hours and then measured proliferation using 
the WST1 assay. This demonstrated that depletion of NUDT21 increased PASMC 
proliferation after 25µM PDGF (Figure7A). I then measured the proliferative phenotype 
of cells isolated from PAH patients. These results demonstrate that PASMC derived 
from patients with Group 1 PH present with an enhanced proliferative response to 
PDGF. Interestingly, overexpressing of NUDT21 from the pcDNA3.1 plasmid attenuated 
the enhanced proliferative phenotype of PAH-derived PASMC (Figure 7A). I used these 
same groups to examine migratory ability. Here I used Boyden chambers with 8µm 
pores (168). These allow cells to pass through but do provide a resistance. Then I 
implement either a control or serum gradient to induce migration. In this experiment I 
see reduced migration in the healthy cells when NUDT21 is reduced by siRNA (Figure 
7B). Overexpression of NUDT21 in PH PASMCs showed no change in migration due to 
sample variability.  
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PASMCs isolated from healthy donors with control siRNA or NUDT21 siRNA are 
stimulated with 25mM PDGF, PASMCs isolated from PAH patients with Empty Vector 
(EV) or NUDT21 over expression vector (OE) are stimulated with 25mM PDGF, WST-1 
Figure 7 Changes in NUDT21 level induces phenotype changes in PASMCs 
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proliferation assay relative to unstimulated (A). PASMCs isolated from healthy donors 
with control siRNA or NUDT21 siRNA in a Boyden chamber assay 1% is no serum 
gradient, 10% is serum gradient (B). PASMCs isolated from PH patients with Empty 
Vector (EV) or NUDT21 over expression vector (OE) in a Boyden chamber assay 1% is 
no serum gradient, 10% is serum gradient (C). Data are shown as mean ± SD.* P ≤ 0.05 
# P≤ 0.05  
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Pathways controlled by NUDT21 mediated APA in PASMCs 
After showing the phenotypic alterations caused by NUDT21 loss I sought to 
understand the pathways that could be driving this change. To do this I utilized human 
PASMCs (Lonza CC-2581) in culture. I used a siRNA to deplete NUDT21 in these cells 
and harvested RNA. This RNA was then put through a library preparation procedure for 
Illumina MiSeq. The sequencing was then performed and the bioinformatics technique 
dynamic analysis of alternative polyadenylation (DaPars) was used to analyze the data 
(169). This algorithm identified 664 shortened transcripts and 350 lengthened 
transcripts (Figure 8A). My next step was to identify the functional pathways that are 
enriched in the shortened data set. To do this I utilized the ConsensusPathDB that not 
only defines pathways by gene product activity but also by protein-protein interactions 
and regulatory interactions (170). In doing this the pathways with the most hits were 
metabolism related genes, extracellular matrix, and cell proliferation (Figure 8B). To 
visualize the changes discovered by the DaPars algorithm the RNA-seq traces for VMA21 
are shown here (Figure 8C). VMA21 is very consistent in its shortening during reduced 
levels of NUDT21 making it an excellent control for NUDT21 mediated 3’UTR APA. 
Finally, I show the confirmation of NUDT21 depletion by siRNA as well as showing that 
this change is sufficient to induce the expression of Col1 and Fn in cell culture (Figure 
8D).  
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Plot of Percent Distal Usage Indexs(PDUI) of control vs change in PDUI in NUDT21 
siRNA treated cells, shortened transcripts blue lengthened orange(A). 
ConsensusPathDB pathways enriched in shortened transcripts (B). Example trace or 
shortened trace, VMA21 (C). Immunoblot of NUDT21, Col1, Fn, and GAPDH from si-con 
and si-NUDT21 treated cells (D). 
  
Figure 8 RNA-seq exposes global APA changes in PASMCs after NUDT21 
depletion 
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Confirmation of NUDT21 mediated APA by RT-PCR 
I then wanted to confirm the shortening events seen in the RNA-seq data. The 
best way to confirm this is by RT-PCR to determine distal polyadenylation site usage. 
To do this two RT-PCR primer sets are designed, one primer set in the coding sequence 
which will measure both a short and long transcript, and one primer set distal of the 
first major poly(A) site which will only measure the distal transcript. The log2 of the 
difference of the Ct value of these primers gives the fold change in dPAS usage. Here I 
verify VMA21 dPAS usage as well as one of the identified shortening targets within the 
ECM pathway from the ConsensusPathDB, HAS2 (Figure 9A). This negative dPAS usage 
indicates a shift from distal to proximal poly(A) usage and shortening of the mRNA 
transcripts. VMA21 showed very robust shortening, as expected, while HAS2 presented 
with a more moderate but nearly a 50% change in dPAS usage. I then measured total 
transcript levels of these genes and demonstrated that both VMA21 and HAS2 are 
significantly increased (Figure 9B). Next, I purified RNA from the isolated pulmonary 
artery of healthy donors and patients with PAH to measure APA. I show that there is a 
trend towards shortening in these samples in both VMA21 and HAS2 (Figure 9C). This 
shortening is also accompanied by increases in total transcripts though VMA21 change 
is non-significant (Figure 9D). These data confirm that NUDT21 depletion leads to 
shortening in select transcripts in PASMCs in culture. While these shortening events 
are not seen in these human samples due to biological variation, transcript levels are 
significantly increased.  
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DPAS usage in VMA21 and HAS2 transcripts after NUDT21 siRNA treatment normalized 
to control siRNA treatment (A). Expression levels of VMA21 and HAS2 using 18S rRNA 
as a control (B). dPAS Usage of VMA21 and HAS2 from PAH pulmonary arteries 
normalized to healthy pulmonary arteries(C). Expression levels of VMA21 and HAS2 
normalized to 18S (D). 
  
Figure 9 RT-PCR verification of shortening in PASMCs 
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Discussion 
A major finding of my research is that NUDT21 levels are reduced in PH patients 
and that depletion of NUDT21 drives the development of PH experimentally. This 
reduction is consistent with the hypothesis that NUDT21 depletion leads to 3’UTR APA 
and changes in mRNA transcripts that lead to PH. In fact, my finding that heterozygous 
deletion of one copy of NUDT21 in mice PASMCs increases the PH that these mice 
acquire in the hypoxia-sugen model is a strong indicator that this mechanism plays an 
important role in the worsening of this disorder. This adds PH to the list of diseases that 
have recently been shown to be partially or whole driven by APA, including several in 
which NUDT21 level are key (112, 114). The results are highly important as they give a 
new target for research and drug development in a disease that is not well controlled 
with current therapies and lacks a curative treatment without transplantation.  
NUDT21 is depleted in glioblastoma tumors and reduced levels of NUDT21 have 
been reported in fibroblast from patients with IPF (163). In these fibroblast, NUDT21 
reduction leads to increased TGFβ and Wnt signaling by altering gene expression 
through APA. These changes result in a more fibrotic phenotype with the increases of 
collagen and fibronectin expression. IPF fibroblast in culture also showed this synthetic 
phenotype but resembled healthier fibroblast with the addition of exogenous NUDT21 
(114). This change in phenotype encouraged me to explore the changes in cell phenotype 
seen in PH and investigate the role of NUDT21 induced APA. My findings indicate that 
healthy PASMCs, with reduced levels of NUDT21 by siRNA have an increased 
proliferative potential when induced by PDGF. This high level of proliferative potential 
matches that seen in PASMCs from patients with PH. This finding is consistent with the 
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proliferative phenotype of patient cells seen in other studies (171). Alternately, migratory 
capacity appears to be reduced with reduced level of NUDT21 in a Boyden chamber 
assay with and without serum gradient. This is an unexpected result as I hypothesized 
that increased migration would occur to accompany increased proliferation as was seen 
in glioblastoma cell lines and is often seen in PASMCs exposed to hypoxia (113, 172). It 
may be though that proliferation increased to such a speed that migration was inhibited 
by the necessity of continued growth. An alternative explanation is that NUDT21 
depletion leads to increased ECM deposition, precluding cell migration. Evidence for 
this is present from PASMCs where increased Fn and Col1a1 expression was observed 
following NUDT21 KD. This would indicate a potential intermediate phenotype with 
increased proliferation and synthesis but reduced migration. These results show that 
NUDT21 depletion regulates the phenotype of PASMC inducing changes similar to 
PASMCs isolated from patients with PH. This is consistent with previous findings of 
increased proliferation in PASMCs in PH (173).  
In PASMC derived from patients with PH, rescuing expression of NUDT21 
reversed their hyper-proliferative phenotype. This indicates that NUDT21 is a highly 
promising target for pharmacological inhibition of PH. One of the challenges of 
targeting NUDT21 is that it is a core member of the cleavage and polyadenylation 
machinery and that activity of this complex is necessary for proper cellular survival. To 
circumvent this problem I have two options, target specifically the pulmonary artery 
cells or look to the interactions within the CFIm complex.  
Increasing expression of NUDT21 in the PASMC would be an excellent 
therapeutic target if it can be done very selectively and subtly. Recent advances in 
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nanoparticle deliver could allow for treatment of PASMCs with a small oligonucleotide 
(174). This was successfully used to target miR-145, which is associated with PAH, in the 
hypoxia-sugen mouse rat model (175). Targeting a miRNA which regulates NUDT21 or 
depletion of an upstream effector with RNAi through this delivery mechanism is a 
potential therapeutic approach for PH. 
An interesting finding was that in PAH all three CFIm complex members are 
downregulated in in the pulmonary artery. Conversely, I see no such change in CFIm59 
or CFIm68 in IPF or IPF + PH samples. This difference could point to a key separator in 
the development of PAH when compared to Group 3 PH. If this is the case it is important 
to further investigate these findings to understand potential interventions. 
Additionally, understanding the role of each CFIm member allows me to target 
interactions within the complex to make more subtle changes to the APA landscape. 
While the exact role of CFIm59 and CFIm68 are unknown, some hypothesize that they 
convey specificity in RNA binding to the complex during the formation of a tetramer 
(176). If this is true, drug screens for NUDT21 mediated APA will likely target the protein 
interactions that bind this complex.  
NUDT21 regulated APA is a broad mechanism that changes the transcriptional 
landscape in a cell. These changes can cause shortening in many genes as seen in HeLa 
cells and caused shortening in over 600 genes in the samples (113). This large number of 
genes that are regulated can make uncovering the smoking gun for changes seen due to 
this APA difficult, thus I first looked at the pathways that were enriched in those genes 
that were shortened by NUDT21 depletion. In my RNA-seq dataset I saw modulation of 
several pathways that are linked to the phenotypic changes in PASMCs I observed in 
 50 
 
patient samples. These include pathways involved in proliferation and migration and 
ECM. In fact, I showed that NUDT21 depletion in PASMCs in cell culture was sufficient 
to cause an increase in Col1A and Fn depositions. This suggests that NUDT21 reduction 
also induces a synthetic phenotype in these cells. As studying each APA event 
discovered to describe the change it induces in PASMC is not feasible I selected a gene 
which as described in the next chapter, is an important driver in PH; this gene is HAS2.   
RNA-seq data can have many factors that cause anomalies in the data including 
hard to sequence regions with repetitive sequences or other sequence features. This 
makes it important to verify this data with other techniques. Here I verified the data 
with additional RT-PCR experiments. This also allowed me to measure gene level 
changes as a result of shortening. This was very exciting, as it revealed that NUDT21 
depletion leads to shortening of the HAS2 mRNA in cell culture as well as patient tissue. 
This change appears to lead to increased transcript level of HAS2. The following 
chapters will discuss the consequences of increased HAS2 in PASMC of patients with 
PH.  
The results shown here indicate that NUDT21 levels are reduced in patient 
samples of PH. This reduction is also recapitulated in the hypoxia-sugen mouse model. 
When mice in this model have additionally reduced levels of NUDT21 the PH symptoms 
are severely worsened, pointing to a role of NUDT21 in the progression of this disease. 
To determine the mechanism that leads to this worsened PH, I described the 
phenotypic changes seen in PASMCs with depleted NUDT21. These phenotypic changes 
resemble differences seen between healthy and PASMC isolated from PH patients. I 
then determined that NUDT21 reduction leads to widespread APA events in PASMCs 
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and that the shortening events are enriched for pathways such as metabolism, 
proliferation and ECM. I verified the shortening and increased expression of one target, 
HAS2 by RT-PCR. Together these results describe an important role for NUDT21 
mediated APA in the development and progression of PH. Understanding the role other 
CFIm members play in these cells as well as more completely describing the APA 
landscape changes seen in patients with PH will allow for targeted research and therapy 
discovery in this newly discovered mechanism of PH development.  
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Chapter 4: Uncovering the role of Hyaluronan in the pathogenesis of PH 
 
 This chapter is based upon research originally published in the British Journal of 
Pharmacology. Collum SD, Chen NY, Hernandez AM, Hanmandlu A, Sweeney H, 
Mertens TCJ, Weng T, Luo F, Molina JG, Davies J, Horan IP, Morrell NW, Amione-
Guerra J, Al-Jabbari O, Youker K, Sun W, Rajadas J, Bollyky PL, Akkanti BH, Jyothula S, 
Sinha N, Guha A, Karmouty-Quintana H. Inhibition of hyaluronan synthesis attenuates 
pulmonary hypertension associated with lung fibrosis. Br J Pharmacol +Q,`. 
 
Introduction 
As discussed previously, the ECM is an integral compartment of all tissues and 
plays a large role in the development of a healthy lung as well as the progression of 
chronic lung diseases (177, 178). To understand the progression of diseases such as PH, 
I must identify the important components of this matrix and dissect the influence these 
molecules have on the cells involved in disease progression (65). The 
glycosaminoglycan, HA, is a key structural component of the lung surrounding large 
vessels and airways but where this molecule plays its most crucial role is signaling 
through multiple pathways to induce cellular changes (160). 
Increased levels of hyaluronan have been observed in patients with IPF and PAH 
(150, 155, 179, 180). Furthermore, overexpression of hyaluronan synthase 2 (HAS2), an 
enzyme responsible for the synthesis of hyaluronan, has been implicated in fibrosis 
(153). Taken together, these observations suggest a role for hyaluronan in the 
pathophysiology of PAH as well as IPF + PH. However, hyaluronan-mediated vascular 
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remodeling and the mechanisms promoting increased hyaluronan synthesis in Group 1 
and Group 3 PH is not fully understood. These observations prompted me to evaluate 
the role of HA in the vasculature in Group 1 PH. I was also prompted to evaluate the 
presence of elevated hyaluronan in patients with IPF and IPF + PH and to assess the 
therapeutic potential of a hyaluronan synthase inhibitor in a murine model of Group 1 
PH as well as PH associated with lung fibrosis.  
4-Methylumbelliferone (4MU), also known as hymecromone, is a FDA approved 
drug for bile therapy and it is also able to inhibit hyaluronan synthesis by depleting the 
cell of uridine diphosphate-glucuronic acid, an essential substrate for all HAS isoforms 
and by down-regulation of HAS2 and 3 mRNA expression (181-183).  Increased levels of 
HA have been measured in PAH both in the plasma of patients as well as in cultured 
PASMCs from these patients (180). Additionally, the monocrotaline rat model shows 
increased HAS2 expression as well as increased HA deposition and aberrant degradation 
of HA (157). 
My results show that therapy with 4MU and conditional genetic deletion of 
smooth muscle HAS2 prevent the development of hallmarks of PH induced by chronic 
exposure to hypoxia and sugen. I also have found that increased hyaluronan was 
associated with remodeled vessels and correlated with increased disease severity in PH 
associated with IPF, as defined by elevated mPAP values. In addition, I report 
improvements in PH but not fibrosis following therapy with 4MU in the bleomycin 
mouse model, which models PH associated with lung fibrosis (184). These observations 
provide evidence for an independent hyaluronan-mediated mechanism in the 
pathogenesis of PH associated with IPF. Furthermore, my results reveal that hyaluronan 
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leads to increased proliferation and stiffness of PASMCs and also affects the ability of 
these cells to migrate in a RhoA-dependent manner. Taken together, these results show 
evidence of a unique mechanism contributing to PH. 
 
Results 
4-Methylumbelliferone (4MU) prevents pulmonary hypertension in the hypoxia-sugen 
model 
To investigate PH without lung parenchyma damage such as seen in Group 1 PH, 
the hypoxia-sugen mouse model has been used (155, 185).  This model recapitulates 
many of the symptoms of this disease including vascular remodeling more resembling 
the pathology seen in PAH patients with heavily exacerbated increases in pulmonary 
blood pressure and eventual loss of cardiac output (55, 185). This model involves 
subjecting the mice to 10% O2 for 28 days with four injections of SU5416 a vascular 
endothelial growth factor receptor (VEGFR) inhibitor. These mice were treated with 
4MU starting at day 14 and measurements and tissues were collected on day 33. In this 
model, I see deposition of HA around the pulmonary vasculature that is reduced by 
4MU treatment (Figure 10A). There is an increase in RVSP at day 28 in hypoxia-sugen 
groups vs controls, this increase was removed by 4MU treatment (Figure 10B). LVSP 
remained unchanged indicating no change to systemic pressures, while a hypoxia-sugen 
induced right ventricle hypertrophy as measured by Fulton index was reduced by 4MU 
treatment (Figure 10C –D).  
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PASMC deletion of HAS2 prevent PH in the hypoxia-sugen model 
As stated earlier the HA producing enzyme HAS2 is upregulated in the 
monocrotaline rat model of PH (157). To further dissect the role of HAS2, which has 
been associated with  multiple disease states (153, 186), in these experiments I also 
utilized the Has2f/f-TaglnCre mouse line. This line is a knockout of the expression of 
HAS2 in vascular smooth muscle cells with no phenotype in nomoxic mice. At day 28 I 
see that RVSP which is increased in control HAS2f/f hypoxia-sugen mice was reduce 
towards normal with LVSP showing no changes (Figure 11A-B). Interestingly there is no 
effect of HAS2 KO on RVH (Figure 11C).  
  
 56 
 
IF-stained lung sections (A) for αSMA (green) and HA (red) from mice treated with 
Normoxia + vehicle, Hypoxia-sugen + vehicle, or Hypoxia-sugen + 4MU. RVSP (B); 
LVSP(C); Fulton index determined from measuring dry weights of RV and LV + 
septum (D). Data are shown as scatter plot showing the mean ± SD. **** P ≤ 0.05, 
significant difference between PBS + vehicle and bleomycin (BLM) + vehicle 
treatment; ANOVA. # P < 0.05, significant difference between BLM + vehicle and BLM 
+ 4MU treatment; ANOVA. The N used for these studies are 10 (Normoxia + vehicle); 
4 (Normoxia + 4MU); 10 (Hx Su + Vehicle); 5 (Hx Su + 4MU) for panel B. Variations 
in N are due to violation of a predetermined criteria: heart rate below 250 BPM at the 
time of LVSP. The scale bar represents 50 μm.  
 
 
Figure 10 4MU prevents pulmonary hypertension in the hypoxia-sugen model. 
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HAS2f/f Normoxia, HAS2f/f hypoxia-sugen, HAS2f/fTaglnCre . RVSP (A); LVSP(B); Fulton 
index determined from measuring dry weights of RV and LV + septum (C). Data are 
shown as scatter plot showing the mean ± SD. * P ≤ 0.05, significant difference 
between HAS2f/f + Normoxia and HAS2f/f + Hx Su; ANOVA. # P < 0.05, significant 
difference between HAS2f/f + Hu Su and HAS2f/f – TaglnCre + Hu Su; ANOVA. The scale 
bar represents 50 μm. The N used for A is 3 (HAS2f/f + Normoxia); 4 (HAS2f/f + Hx Su); 
5 (HAS2f/f – TaglnCre + Hu Su). Variations in N are due to violation of a predetermined 
criteria: heart rate below 250 BPM at the time of RVSP or LVSP. 
  
Figure 11 PASMC KO of HAS2 prevents pulmonary hypertension. 
 58 
 
Hyaluronan is elevated in patients with Group 3 pulmonary hypertension 
HA deposition is increased in IPF and HA levels are associated with PH 
secondary to COPD (153, 158). No study has shown a link between HA and IPF + PH. I 
stained lung sections from patients diagnosed with IPF and those with IPF + PH. I found 
increased hyaluronan levels, observed histologically, in IPF patients compared to 
controls. This increase appeared to be enhanced further in patients with IPF + PH in 
areas adjacent to the smooth muscle but not in the endothelial layer (Figure 12A). 
Interestingly, increased hyaluronan deposition was observed in areas rich in vascular 
remodeling (Figure 12A). Transcript levels of HAS1, HAS2 and HAS3 (Figure 12B–D) from 
isolated lung sections revealed a significant correlation between elevated HAS2 and 
HAS3 expression but not HAS1 expression levels and increased mPAP values for patients 
with IPF (Figure 12B–D). Similarly, immunofluorescence for HAS2 and HAS3 revealed 
increased signals for HAS2 and HAS3 in remodeled vessels of patients with IPF + PH 
but not in IPF or normal (Figure 13A). Immunoblots for HAS1, HAS2 and HAS3 revealed 
increased expression of HAS1 and HAS2 in IPF + PH samples compared with normal 
and in IPF + PH compared with IPF groups (Figure 13B). Taken together these results 
suggest that hyaluronan accumulation is present in fibrotic lung diseases and is 
increased in patients with an additional diagnosis of PH. 
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Lung sections double stained for α-smooth muscle actin (α-SMA; red signals) and 
hyaluronan (blue signals) from representative normal lungs (top panel) or patients with 
IPF (middle panel) or IPF + PH (bottom panel) (A). Linear regression and Spearman 
correlation analysis for mRNA levels for HAS1 (B; r = 0.1375, P>0.05), HAS2 (C; r = 0.6110, 
P<0.05), HAS3 (D; r = 0.5144, P<0.05), HYAL1 (E; r = 0.2394, P>0.05), HYAL2 (F; r = 
0.5932, P<0.05) and HYAL3 (G; r = 0.3560, P>0.05) ratio to geometric mean of control 
genes HPRT1 and SDHA against mPAP from patients with IPF. The scale bar represents 
100 μm. n = 6 (Control); 10 (IPF); 9 (IPF + PH). PH is defined as mPAP ≥25 mmHg. 
 
 
 
 
 
 
 
Figure 12 Increased hyaluronan levels and degradation in Group III PH. 
 61 
 
Immunofluorescence (IF) for HAS2 (red signals), or HAS3 (green signals) and αSMA 
(white signals) for normal IPF and IPF + PH vessels (A); scale bar represents 50 μm. (B) 
Immunoblots for HAS1–3, HYAL1–3, CD44 and βactin from 3 normal, 3 IPF and 3 IPF + 
PH lung tissue samples. Linear regression and Spearman correlation between NRF2 
expression levels and mPAP values for patients with IPF with or without a diagnosis of 
PH (C). Linear regression and Spearman correlation with CD44 expression levels (D). 
Expression levels for HAS1–3 and HYAL1–3 showing direct comparisons between IPF 
and IPF + PH samples (E). Significance levels * P ≤ 0.05 refers to comparisons between 
IPF and IPF + PH values.  
Figure 13 HAS2, HAS3, NRF2 and CD44 levels in human samples. 
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Increased hyaluronan degradation in Group 3 pulmonary hypertension 
Hyaluronan can be degraded into low molecular weight fragments by 
hyaluronidases and increased ROS (187, 188). Interestingly I report a significant 
correlation between enhanced expression of hyaluronidase 2 (HYAL2) and mPAP 
(Figure 12F) and elevated HYAL2 signals by immunoblots between IPF and normal but 
not between IPF and IPF + PH. I also show increased protein levels for HYAL3 between 
IPF and normal lung but no increases between IPF + PH and IPF but similar results were 
not seen for HYAL1 or HYAL3. (Figure 12E–G) Immunoblots for HYALs revealed an 
overall increase in IPF compared with normal groups and a further increase in IPF + PH 
groups compared with IPF (Figure 13B). Finally, I report a significant correlation 
between increased expression of Nrf2, a marker of increased oxidative stress, and 
elevated mPAP (Figure 13C). Small MW hyaluronan fragments have been reported to 
interact with CD44 to mediate pathogenic effects and I therefore measured CD44 levels 
(177, 189). However, my data appears to show a reduction in CD44 protein levels despite 
a correlation between increased CD44 and mPAP levels (Figure 13D, E). Expression 
levels of all HAS and HYALs (IPF vs. IPF + PH) are shown in Figure 13. Taken together, 
these observations show increased hyaluronan deposition in IPF and IPF + PH and 
suggest that degradation of hyaluronan to smaller MW fragments is mediated by 
enhanced expression of HYALs and the presence of ROS. 
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4-Methylumbelliferone (4MU) reduces hyaluronan levels in a model of lung fibrosis and 
PH 
In this experiment, I treated mice exposed to bleomycin or vehicle, with 4MU 
starting on day 15, consistent with previous studies from the lab where changes in the 
lung parenchyma are apparent at this time point (190). On day 33, physiological 
readouts and tissues were collected (Figure 14A). This is the intraperitoneal bleomycin 
model that creates a more chronic fibrosis compared to the more commonly utilized 
intratracheal bleomycin model. This model produces fibrosis progression from the 
distal portion of the lung more in line with that seen in patients. Eight twice weekly 
injections are performed and then the model progresses until day 33. BLM induces lung 
fibrosis due to the relative lack of bleomycin hydrolase in the lung (191).   
Hyaluronan levels observed by immunohistochemistry (IHC) show increased 
hyaluronan deposition in bleomycin-exposed mice that were treated with 4MU therapy 
(Figure 14B). In line with this, bronchoalveolar lavage fluid (BALF) revealed a significant 
elevation of HA in bleomycin-exposed mice that was attenuated by 4MU treatment 
(Figure 14C). These observations were consistent with increased levels of Has1, Has2 and 
Has3 expression in bleomycin-exposed mice (Figure 14D-F) 4MU attenuated Has2 and 
Has3 but not Has1 expression (Figure 14D–F). Analysis of hyaluronidases demonstrated 
increased protein levels of Hyal1 and Hyal2 in bleomycin and bleomycin + 4MU 
treatment groups compared to PBS consistent with increased Hyal2 but not Hyal1 or 
Hyal3 mRNA expression levels (Figure 15B–D). Transcript levels for Nrf2 were elevated 
in bleomycin, compared to PBS, groups (Figure 15E). These observations echo my 
studies with human lung, showing evidence for increased hyaluronan fragment 
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degradation in experimental lung fibrosis. Here I also measured CD44 levels and I report 
increased both protein and mRNA levels in bleomycin-exposed mice (Figure 15A, F). 
  
 65 
 
Experimental mice are treated biweekly for 4 weeks with bleomycin (BLM; 0.035 U/g, 
i.p.) or PBS; 20 mg/kg/day 4MU or normal chow was administered beginning on day 15 
until the end of the experiment (A). IHC (B) for hyaluronan from PBS + vehicle, PBS + 
4MU, BLM + vehicle and BLM + 4MU treatment groups. Hyaluronan levels determined 
from BALF (C); mRNA levels from lung lysates for Has1 (D); Has2 (E) and Has3 (F) using 
Figure 14 Reduction of hyaluronan levels with 4MU in lung fibrosis and PH. 
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TATA-box binding protein (TBP). Data are shown as scatter plots showing the mean ± 
SD. * P ≤ 0.05, significant difference between PBS + vehicle and BLM + vehicle 
treatment; ANOVA. # P < 0.05, significant difference between BLM + vehicle and BLM 
+ 4MU treatment; ANOVA. The scale bar represents 50 μm. The N used for these studies 
are 5 (PBS + vehicle); 6 (PBS + 4MU); 8 (BLM + vehicle); 7 (BLM + 4MU) for panel C and 
5 (PBS + vehicle); 6 (PBS + 4MU); 8 (BLM + vehicle); 5 (BLM + 4MU) for panels D–F. 
Variations in N are due to violation of a predetermined criteria: presence of blood in 
BALF (C) or repeatedly poor RNA quality and loss of sample (D–F). 
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Immunoblots of 2 PBS [+vehicle], 3 BLM [+vehicle] and 3 BLM + 4MU for Hyal1, Hyal2, 
Hyal3, Cd44 and βactin (A). Transcript levels for Hyal1 (B), Hyal2 (C), Hyal3 (D), Cd44 
(E) and Nrf2 (F). The N number used for these studies are 5 (PBS + Vehicle); 6 
(PBS + 4MU); 8 (BLM + Vehicle); and 5 (BLM + 4MU). Significance level * P ≤ 0.05 refers 
to ANOVA comparisons between PBS + Vehicle and BLM + Vehicle treatment groups. 
Variations in the N number are due to violation of a predetermined criteria: repeatedly 
poor RNA quality and loss of sample (B-D). 
Figure 15 Hyaluronidases in mouse samples. 
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4-Methylumbelliferone (4MU) prevents vascular remodeling and PH 
Using a mouse model of lung fibrosis and PH, I show increased vascular α-
smooth muscle actin (αSMA) deposition in addition to Has1, Has2 or Has3 expression 
consistent with vascular remodeling in bleomycin-exposed mice compared to controls 
(Figure 16A) (190). Treatment with 4MU in bleomycin-exposed mice led to a reduction 
in αSMA deposition and Has1, Has2 or Has3 expression levels observed by 
immunofluorescence (Figure 16A) and assessed morphometrically (Figure 16B). These 
changes are in-line with physiological readouts of pulmonary hypertension such as 
RVSP where I report increased pressures in bleomycin-exposed mice that were 
significantly attenuated in the bleomycin + 4MU group (Figure 16C). Similarly, the 
Fulton index, a measure of RVH revealed increased values in bleomycin-exposed mice 
that were significantly inhibited in 4MU-treated bleomycin-exposed mice (Figure 16D). 
I also report a significant improvement in arterial oxygenation (SpO2) in bleomycin+ 
4MU treated mice compared with bleomycin-exposed mice where reduced oxygenation 
is apparent compared to controls (Figure 16E). No changes in LVSP or heart rate were 
observed between treatment groups (Figure 17A, B). Taken together my data show that 
4MU can prevent vascular remodeling and the subsequent development of PH in the 
model. In addition, I performed bioanalysis by LC–MS/MS to determine the levels of 
4MU and its metabolite 4-methylumbelliferyl-β-D-glucuronide (4MUG) from plasma 
samples. Interestingly I report increased levels of 4MU in bleomycin-exposed 4MU-
treated mice compared with PBS-exposed 4MU groups (Figure 17C). 4MUG levels were 
elevated in both bleomycin and PBS exposed mice that received 4MU in the diet (Figure 
17D).  
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IF-stained lung sections (A) for αSMA (white or red signals) and Has1 (violet/purple 
signals); Has2 (green signals); or Has3 (green signals) from mice treated with PBS + 
vehicle, bleomycin (BLM) + vehicle, or BLM + 4MU. Vascular remodeling determined 
Figure 16 4MU prevents vascular remodeling and pulmonary hypertension. 
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morphometrically (B); RVSP (C); Fulton index determined from measuring dry weights 
of RV and LV + septum (D); arterial oxygen (SPO2) determined by pulse oximetry (E) 
from PBS + vehicle, PBS + 4MU, BLM + vehicle and BLM + 4MU treatment groups. Data 
are shown as scatter plot showing the mean ± SD. * P ≤ 0.05, significant difference 
between PBS + vehicle and BLM + vehicle treatment; ANOVA. # P < 0.05, significant 
difference between BLM + vehicle and BLM + 4MU treatment; ANOVA. The scale bar 
represents 50 μm. The N used for these studies are 6 (PBS + vehicle); 6 (PBS + 4MU); 7 
(BLM + vehicle); 5 (BLM + 4MU) for panel B; and 10 (PBS + vehicle) for panel B and 10 
(PBS + 4MU); 10 (BLM + vehicle); and 8 (BLM + 4MU) for panels C, D and E. Variations 
in the N are due to violation of a predetermined criteria: inadequate inflation of the 
lung (C) or heart rate below 250 BPM at the time of RVSP or inability to perform pulse 
oximetry determination (C–E). 
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Left ventricle systolic pressure (LVSP) (A) and heart rate (B) from PBS (PBS) + vehicle, 
PBS + 4MU, bleomycin (BLM) + vehicle, and BLM + 4MU treatment groups. Data is 
shown as a scatter plot showing the mean ± SD.  The N number used for these studies 
are 8 (PBS + Vehicle); 7 (PBS + 4MU); 7 (BLM + Vehicle); and 6 (BLM + 4MU) for panel 
A and 10 (PBS + Vehicle); 10 (PBS + 4MU); 10 (BLM + Vehicle); and 8 (BLM + 4MU) for 
panel B. Plasma levels for 4-methylumbelliferone (4MU) and its metabolite: 4-
methylumbelliferyl-β-D-glucuronide (4MUG) from PBS + Vehicle; PBS + 4MU; 
BLM + Vehicle; and BLM + 4MU treatment groups. n = 5 for all groups. Significance 
level * P ≤ 0.05 refers to ANOVA comparisons between PBS + Vehicle and BLM + Vehicle 
treatment groups. # P ≤ 0.05 refers to ANOVA comparisons between PBS + 4MU and 
BLM + 4MU treatment groups. Variations in the N number are due a violation of a 
predetermined criteria: heart rates below 250 BPM at the time LVSP determination (A) 
or below 250 BPM at the time of RVSP determination (B).  
Figure 17 Additional hemodynamic data and 4MU / 4MUG levels in plasma. 
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Fibrotic deposition is not altered in 4MU-treated mice 
Numerous studies have shown a role for hyaluronan in the pathophysiology of 
lung fibrosis (152, 153, 180). Based on these observations, I anticipated that 4MU 
treatment would diminish the extent of fibrotic deposition in bleomycin-exposed mice. 
Interestingly, I report that treatment with 4MU did not reduce the extent of fibrotic 
scarring in the lungs as shown histologically (Figure 18A) or following Ashcroft score 
grading (Figure 18B). These observations are consistent with Col1a1 and Fn1 transcript 
levels showing elevated expression in bleomycin-exposed mice that were not inhibited 
in bleomycin + 4MU mice (Figure 18C, D). Consistent with these observations, an 
immunoblot for fibronectin (FN) shows increased FN signals in bleomycin-exposed 
mice compared with controls, that were not altered in bleomycin + 4MU mice (Figure 
18E) and staining for SMA shows no difference in myofibroblast deposition between 
bleomycin-exposed mice following vehicle or 4MU treatment (Figure 18F). Collectively, 
these results suggest that 4MU, although able to inhibit vascular remodeling, may not 
influence fibrotic deposition at the dose and regimen used in this study. 
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Masson's trichome (A); Ashcroft scores (B); transcript levels for Col1a1 (C) and Fn1 (D); 
and immunoblots for FN and β-actin (E) from PBS + vehicle, PBS + 4MU, bleomycin 
(BLM) + vehicle and BLM + 4MU treatment groups. Lung sections IF stained for αSMA 
(green signals) and counterstained with DAPI (blue signals) (F) from BLM + vehicle or 
BLM + 4MU treatment groups. Data are shown as scatter plot showing the mean ± SD. 
* P ≤ 0.05, significant difference between PBS + vehicle and BLM + vehicle treatment; 
ANOVA. The scale bar represents 50 μm. The N used for these studies are 5 
Figure 18 Fibrotic deposition is maintained in 4MU-treated mice. 
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(PBS + vehicle); 5 (PBS + 4MU); 5 (BLM + vehicle); and 5 (BLM + 4MU) for panel B and 
5 (PBS + vehicle); 6 (PBS + 4MU); 8 (BLM + vehicle); and 5 (BLM + 4MU) for panels C 
and D. Variations in the N are due to violation of a predetermined criteria: repeatedly 
poor RNA quality and loss of sample (B–D).   
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4MU treats established PH 
I next examined the capability of 4MU to treat established PH. In this 
experiment, mice received 4MU or vehicle (control chow) starting on day 33 (Figure 
19A), a time point where PH is present in the model (Figure 19A), for 14 days. Consistent 
with my previous experiment, 4MU resulted in reduced mRNA expression of Has1, Has2 
and Has3 observed from flash-frozen lung samples and vascular protein levels shown by 
immunofluorescence (IF) (Figure 19B–D). Remarkably, I report higher RVSP levels on 
day 47 in mice treated with control chow compared with mice on day 33, that are 
drastically attenuated following treatment with 4MU (Figure 19E). Interestingly, 4MU 
did not appear to affect RVH when therapy started on day 33 (Figure 19F). No changes 
in LVSP were observed in these mice (Figure 19G). Consistent with my previous results, 
4MU did not affect fibrotic deposition as observed histologically and through Ashcroft 
scores (Figure 6A, B). RT-PCR for Col1a1, Col1a2 and Col3a1 did not reveal differences 
between bleomycin + 4MU and bleomycin + vehicle treatment groups (Figure 20C–E). 
Interestingly, no significance differences between Hyal1, Hyal2, Hyal3 and CD44 at the 
mRNA or protein level were detected between bleomycin + vehicle and bleomycin + 
4MU groups (Figure 20F–I). However, reduced levels for RhoA guanine nucleotide 
exchange factor 25 (GEFT), a signaling protein seen to act downstream of CD44 (192), 
were found in bleomycin-exposed 4MU-treated mice compared to bleomycin-exposure 
and vehicle treatment (Figure 20I). Determination of hyaluronan fragment size in 
isolated lung tissue revealed increased LMW hyaluronan fragments in bleomycin-
exposed mice compared to controls; 4MU treatment reduced total hyaluronan fragment 
size, particularly LMW-HA (Figure 20J). Taken together, these results highlight the 
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properties of 4MU in reversing PH associated with lung fibrosis, despite not inhibiting 
FN and Col1a1 levels. These results also show that 4MU does not appear to have an effect 
on Hyal expression levels but that it may also alter GEFT levels that may be important 
for PH. 
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Here mice are treated biweekly for 4 weeks i.p. with bleomycin (BLM; 0.035 U·g−1, i.p.) 
or PBS; 20 mg·kg−1·day−1 4MU or normal chow was administered beginning on day 33; 
once PH was established for 2 weeks, measurements were performed on day 47 (A). 
mRNA expression levels and IF staining for Has1 (violet/purple signals) and αSMA 
(white signals) (B); Has2 (red signals) and αSMA (white signals) (C) and Has3 (green 
signals) and αSMA (white signals) (D) normalized to β-actin (Actnb). RVSP (E), RVH 
determined from measuring dry RV and LV + septum masses (F); and LVSP (G); BLM + 
vehicle and BLM + 4MU treatment groups. Data are shown as scatter plot showing the 
mean ± SD. * P ≤ 0.05, significant difference between BLM + vehicle and BLM + 4MU 
treatment; unpaired Student's t-test. The N used for these studies are 5 (BLM + vehicle); 
and 5 (BLM + 4MU). 
Figure 19 4MU attenuates established pulmonary hypertension. 
 78 
 
Masson's trichrome-stained lung sections (A) and Ashcroft scores (B) from bleomycin 
(BLM) or BLM + 4MU-treated mice. Expression levels of Col1a1 (C), Col1a2 (D), Col3a1 
(E), Hyal1 (F), Hyal2 (G) and Hyal3 (H) normalized to β-actin (Actnb). immunoblots 
(I) for Hyal1, Hyal2, Hyal3 Cd44, GEFT and β-actin for four representative mice from 
Figure 20 4MU does not affect fibrotic deposition in established PH. 
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BLM + vehicle and BLM + 4MU treatment groups. Hyaluronan fragment size (J) from a 
PBS (lane 1), BLM + 4MU (lane 2) or a BLM-exposed (lane 3) lung. The red rectangle 
highlights an area with LMWHA fragments showing a greater density in lane 3. Data 
are shown as scatter plot showing the mean ± SD (Panels B–H). The N used for these 
studies are 5 (BLM + vehicle); and 5 (BLM + 4MU). 
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Increased vascular hyaluronan-binding protein 2 (HABP2) is observed 
Studies have shown that HABP2, an extracellular serine protease that binds 
hyaluronan and has been implicated in mediating endothelial dysfunction (193). 
Interestingly, in my study, I show increased levels of HABP2 in remodeled vessels from 
mice exposed to bleomycin compared with controls, that are subsequently reduced in 
bleomycin-exposed mice treated with 4MU (Figure 21). In line with these observations, 
I report increased HABP2 in and adjacent to remodeled vessels in the lung from patients 
with IPF + PH compared to IPF and normal lungs (Figure 22A). In support of these data, 
an immunoblot for HABP2 revealed increased levels in IPF + PH patient samples 
compared to IPF or normal lungs (Figure 22B, C). Studies have implicated increased 
signaling of HABP2 and hyaluronan complexes through a RhoA mechanism (193). As 
such, I examined whether increased signals for GEFT, a protein that interacts with Rho 
GTPases and is involved in the activation of RhoA and subsequent contraction of 
vascular smooth muscle (194). Indeed, I report increased GEFT in lung lysates from 
patients with IPF + PH compared to normal or IPF alone (Figure 22D, E). Remarkably, 
increased HABP2 was only observed in remodeled vessels and not in fibrotic lesions of 
the lung as observed in mice lungs exposed to bleomycin and treated with vehicle or 
4MU or in fibrotic lesions of patients with IPF + PH (Figure 23). These observations 
suggest that the interaction between HABP2 and hyaluronan and subsequent RhoA 
activation may be a unique mechanism contributing to PH associated with lung fibrosis. 
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Lung sections triple immunofluroescently stained for αSMA (turquoise signals), HABP2 
(yellow signals) and hyaluronan (violet/purple signals) and counterstained with DAPI 
(white/grey signals) from PBS, bleomycin (BLM) or BLM + 4MU-exposed mice. The 
scale bar represents 50 μm. 
  
Figure 21 4MU reduces vascular HABP2 levels. 
 82 
 
Lung sections from a pulmonary vessel showing triple immunofluroescent staining for 
αSMA (turquoise signals), HABP2 (yellow signals) and HA (violet/purple signals) and 
counterstained with DAPI (white/grey signals) (A); immunoblots for HABP2 and 
GADPH (B); densitometry for HABP2 normalized to GADPH (C); immunoblots for 
GEFT and β-actin (D); and densitometry for GEFT normalized to β-actin (E) from 
normal lung tissue and from lung explants from patients with IPF and IPF + PH. The 
scale bar represents 50 μm. * P ≤ 0.05, significant difference between normal and IPF + 
PH values. 
  
Figure 22 Increased vascular HABP2 in patients with IPF and IPF + PH. 
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Lung sections triple immunofluroescently (IF) stained for αsmooth muscle actin (α-
SMA/ turquoise signals), HABP2 (yellow signals), and hyaluronan (HA; violet/purple 
signals) and counterstained with DAPI (white/grey signals). No HABP2 signals are 
observed in the lung parenchyma from patients with IPF. 
Figure 23 HABP2 is not expressed in the lung parenchyma. 
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Hyaluronan fragments affect PASMC properties 
Using human PASMC from normal areas of resected cancer tissue, I demonstrate 
that MMW and LMW hyaluronan fragments lead to increased proliferation of PASMC 
that is inhibited by fasudil, a Rho kinase inhibitor (Figure 24A); no significant 
differences were seen in cytotoxicity between treatment groups (Figure 24B). I next 
examined the capacity of these cells to migrate using a 3D cell culture protocol (195). In 
these experiments, I report reduced cell migration in PASMC following treatment with 
LMW-HA and ULMW-HA that was reversed following treatment with fasudil (Figure 
24C). Surprisingly, atomic force microscopy (AFM) experiments revealed that MMW 
and ULMW-HA fragments were both able to increase PASMC stiffness that was reversed 
using fasudil (Figure 24E). AFM measurements were performed in the center of the cell 
(Figure 24F). Taken together, these results demonstrate that hyaluronan fragments are 
able to cause stiffening of PASMC and that LMW-HA induced increased proliferation 
but reduced motility of these cells in a Rho-dependent manner that contribute to the 
pathophysiology of PH associated with lung fibrosis. 
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Cellular proliferation (A) and cytotoxicity (B) from cells exposed to HMW, MMW, LMW 
or ULMW hyaluronan treated with PBS or fasudil (100 μM). Migration assay for MMW, 
LMW and ULMW (C).  Staining for Ki67, HABP2 and GEFT in cell culture after 
treatment with ULMW HA and Fasudil (D). Atomic force microscopy experiments 
showing increased cells stiffness using Young's modulus for PASMC treated with media 
only, MMW or ULMW HA (E). Detail of the positioning of the AFM tip on the centre of 
a PASMC (F). * P ≤ 0.05, significant difference between media and MWM + PBS, LMW 
+ PBS or ULMW + PBS experimental, ANOVA. # P ≤ 0.05, significant difference between 
PBS and fasudil treatment groups; unpaired Student's t-test.  
Figure 24 Hyaluronan affects PASMC properties. 
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Discussion 
A major finding of this study was that HAS2 expression is associated with 
increased PH in patients with IPF. Additionally, we see increases in HAS3 and Hyal2 
expression. Furthermore, these expression changes are associated with staining for HA 
in patients with IPF, including those with secondary PH, near the pulmonary 
vasculature. These findings are confirmed in the bleomycin model of lung fibrosis and 
PH. Provocative results from this study demonstrate that treatment with 4MU, a 
hyaluronan synthesis inhibitor that also targets HAS mRNA expression, prevented the 
development of PH and treated established PH associated with lung fibrosis. My results 
are remarkable as they show that 4MU is able to attenuate RVSP and vascular 
remodeling, but it does not appear to affect fibrotic deposition in the lungs. In a second 
model of PH, initial studies indicate 4MU also reduced RVSP and RVH while deletion 
of the HAS2 gene from vascular smooth muscle cells was able to reduce RVSP without 
changes to RVH. These results point at a unique mechanism for hyaluronan in the 
pathogenesis of PH. Novel findings from my study demonstrate increased expression of 
HABP2 and GEFT in remodeled vessels from patients with Group 3 PH and in 
experimental models of PH and lung fibrosis. I also show that hyaluronan fragments 
induce increased PASMC proliferation and stiffness of the cell and also affect cellular 
migration in a RhoA-dependent fashion. Taken together, my results demonstrate that 
elevated hyaluronan is modulating PH associated with lung fibrosis that can be treated 
by inhibiting hyaluronan synthesis or RhoA activation. These results are significant 
given the poor prognosis of patients with chronic lung diseases with an additional 
diagnosis of PH, where no treatment options are available(196). 
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Elevated hyaluronan has been reported in lung diseases including IPF and PH 
and in PH associated with chronic obstructive pulmonary disease as well as PAH (153, 
155, 158, 180, 189, 197). Consistent with these findings, I report increased hyaluronan 
levels in IPF compared with normal lungs that are elevated further in patients with a 
diagnosis of PH. Interestingly, my data show evidence for elevated HAS enzymes in 
disease. These findings are significant as HAS2 has been shown to promote senescence 
in fibroblasts in pulmonary fibrosis suggesting a similar pathogenic role for HAS2 in 
PASMC (198). HMW hyaluronan fragments are typically associated with beneficial 
properties with smaller fragments inducing pathogenic effects through its interaction 
with cell membrane receptors such as CD44 (189, 199). Hyaluronidases and ROS have 
been shown to degrade HMW hyaluronan to lower molecular weight fragments. In line 
with this, I report increased levels of several hyaluronidases in IPF in addition to a 
correlation between NRF2 transcripts and elevated mPAP levels in patients in IPF. 
Taken together, these studies demonstrate that hyaluronan synthesis is up-regulated, 
perhaps as a protective response, but that the higher levels of hyaluronidases and 
oxidative stress lead to degradation of hyaluronan to pathogenic factors. Although the 
mechanisms that lead to elevated expression of HAS and HYALs are not the focus of 
this study, I anticipate that activation of the adenosine A2B receptor modulates this 
process, consistent with the notion of elevated adenosinergic-hypoxic axis in PH 
associated with IPF and the role of adenosine in modulating hyaluronan synthesis 
associated with chronic obstructive pulmonary disease (158). It is well known that 
higher molecular fragments of hyaluronan are beneficial (180). In addition, hyaluronan 
has been shown to promote progenitor cell renewal and prevent severe fibrosis in mice 
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(200). Therefore, an alternative approach to inhibiting hyaluronan synthases would be 
to prevent the degradation of hyaluronan to the more pathogenic smaller fragments by 
developing selective inhibitors of hyaluronidases. Interestingly, two patients from the 
study cohort were treated with N-acetylcysteine, a compound known to inhibit 
hyaluronidases (201). It is worth noting that these patients did not have a diagnosis of 
PH and one had the lowest levels of mPAP in the cohort. 
The mechanisms that lead to the development of PH associated with chronic 
lung diseases are not fully understood (17, 202). Traditional views suggest that 
eliminating the underlying chronic lung disease such as fibrosis will result in the 
improvement of PH outcomes. Although studies have shown that inhibition of fibrotic 
deposition or airspace enlargement in the lungs improves PH, the identification of a 
unique mechanism leading to PH associated with lung fibrosis has been elusive (158, 
190). Surprisingly, my results show that inhibiting hyaluronan synthesis by 4MU 
prevents the development of PH and reduces established PH without affecting fibrotic 
deposition in the lungs. An explanation for these results may reside in the fact that 
although hyaluronan levels were reduced, the levels may still be high enough to 
maintain fibroproliferative lesions. Alternatively, findings demonstrating a protective 
role for hyaluronan in severe fibrosis could also help explain my findings (200). 
These effects are consistent with reduced Has transcripts and vascular Has levels 
seen by IF. Consistent with previous publications showing a beneficial effect for 4MU 
my results demonstrate that 4MU treatment attenuated bleomycin-induced vascular 
remodeling, elevated RVSP and RVH and led to an increased arterial oxygenation (203-
205). It is important to note that in experiments where 4MU was administered in 
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established PH (on day 33 vs. 15), RVSP but not RVH was attenuated. In this model, I 
believe that lung vascular remodeling precedes RVH; thus, I anticipate that in already 
established PH, a longer treatment time may be necessary to have an effect on RVH. 
Despite this, these results point at a potential use for 4MU in patients with IPF with the 
aim of preventing the development of PH. Lowering elevated mPAP levels in patients 
with Group 3 PH and preventing the development of PH in patients with IPF would be 
a valuable clinical outcome, as PH in IPF is strongly associated with mortality (17). 
However, it is important to note that despite these observations, there is still 
controversy over whether treating PH in the setting of IPF improves survival, despite 
early improvements in functional status and quality of life (206). However, in those 
studies, the effects of a vasodilator were evaluated, and it remains possible that 
therapies that are aimed to alter the process of vascular remodeling would have greater 
beneficial effects (206). It is also important to mention that patients with IPF + PH who 
have a lung transplant, have worse outcomes than those without PH, suggesting that 
treating PH might lead to similar outcomes to those patients with IPF and no PH. 
Moreover, reducing elevated mPAP levels in patients with chronic lung diseases and 
out-of-proportion PH would enable these patients to become eligible for lung 
transplantation, a procedure that is often unavailable for them. The doses of 4MU I have 
used here, while lower than some studies, especially those that characterized the 
pharmacokinetics of this drug, were able to produce a physiological response and 
detectable levels in the plasma of the treated animals (207). This dose is similar to the 
dose used in a human clinical study in motor disorders of the bile ducts (208). These 
results may indicate that inhibition of HA production in the lung is possible with 
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comparatively lower doses of 4MU, leading to the potential to use less drug and 
consequently produce fewer side effects. 
In my effort to identify how elevated hyaluronan may play a role in the 
development of PH, I identified increased expression of HABP2 in remodeled vessels of 
patients with Group 3 PH and in experimental models of PH and lung fibrosis. 
Interestingly, increased HABP2 appeared to be localized in remodeled vessels and was 
not observed in areas rich in fibroproliferative injury. Increased HABP2 has been shown 
to down-regulate vascular integrity through a RhoA-dependent mechanism (193). In 
line with this, I report increased expression of GEFT, an essential component of the 
RhoA pathway activation that has been linked to hyperplasia of vascular smooth muscle 
cells (209). In subsequent experiments, I demonstrated that LMW and ULMW 
hyaluronan fragments induced increased proliferation of isolated human PASMC that 
were inhibited by the RhoA inhibitor fasudil. These studies are consistent with the 
capacity of hyaluronan to induce cellular proliferation and demonstrate a novel role for 
fasudil in hyaluronan-induced PASMC proliferation (189, 197, 210). Furthermore, in 
contrast to published experiments showing increased cellular migration by hyaluronan, 
my studies show that cellular migration PASMC is drastically inhibited by LMW and 
ULMW hyaluronan fragments in a RhoA-dependent manner (189, 197, 199). These 
differences may derive from the fact that most cells where hyaluronan-induced cellular 
migration has been reported are in cancer cells that are prone to migration. However, 
my results showing reduced cellular migration are in line with increased PASMC 
stiffness observed by AFM following exposure to hyaluronan (189, 197, 210). These 
observations are consistent with increased vascular stiffness induced by hyaluronan 
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accumulation in the aorta (177). Interestingly, in this study, increased proliferation of 
vascular smooth muscle cells was also associated with increased hyaluronan 
accumulation. This is consistent with experiments showing increased PASMC 
proliferation when grown in substrates with similar stiffness as that seen in distal vessels 
in PH (162). Taken together, my results show that increased HABP2 and GEFT are 
present in remodeled vessels of patients with Group 3 PH. My data show evidence that 
hyaluronan fragments are able to induce both cellular proliferation and increased 
stiffness of PASMC while attenuating migration of these cells that contribute to the 
development of PH. These findings would support the use of fasudil for the treatment 
of Group 3 PH. Indeed, fasudil has been used in Group 1 PH where it has shown 
promising results and is effective in models of lung fibrosis , although it’s potential as a 
treatment for Group 3 PH has not yet been fully evaluated (179, 211, 212). Another 
promising approach is the development of inhibitors of HABP2, a protein that is 
strongly associated with the development of Group 3 PH and has recently been linked 
with cancer (213). 
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Chapter 5: Identifying the role of hyaluronan in Combined Pulmonary Fibrosis 
and Emphysema 
 
This chapter is based upon research originally published in Disease Models and 
Mechanisms. Collum SD, Molina JG, Hanmandlu A, Bi W, Pedroza M, Mertens TCJ, 
Wareing N, Wei W, Wilson C, Sun W, Rajadas J, Bollyky PL, Philip KM, Ren D, 
Thandavarayan RA, Bruckner BA, Xia Y, Blackburn MR, Karmouty-Quintana H. 
Adenosine and hyaluronan modulate lung fibrosis and pulmonary hypertension in 
combined pulmonary fibrosis and emphysema (CPFE). Dis Model Mech 2019. 
 
Introduction 
In the previous chapter I have demonstrated the important role that HA plays in 
the development of PH. I also indicate that though HA is associated with pulmonary 
pressure increases, patients with IPF have increased HA over healthy individuals. This 
is in line with previous studies indicating that HA signaling is important for invasive 
fibroblast during the progression to severe lung fibrosis (153). In fact HA depositions 
has long been a hallmark of lung fibrosis (214).  
Continued research has shown that HA deposition and degradation play an 
important role in COPD as well. Patients with severe COPD have increased levels of HA 
and HYAL2 compared to control subjects (149). HA and HYAL activity have strong 
correlations with survival time in patients with COPD (215). Additionally, a previous 
publication from the Karmouty lab has shown increased levels of HA associated with 
PH secondary to COPD in patient samples (158).  
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However, whether abnormal HA synthesis and destruction are present in CPFE 
is not known. CPFE is a complex disease where both fibrotic matrix deposition, similar 
to IPF, is present and airspace enlargement, a hallmark of COPD, is also present in the 
same lungs. Up to 90% of patients with CPFE also develop PH, a sever complication for 
this disease. My results in the previous chapter, showing a mechanistic role of HA in 
PH, and previous data showing strong correlation for HA with IPF and COPD indicate 
that it may be a common mechanism that plays a role in CPFE. This motivated me to 
investigate the role of HA in CPFE to investigate the shared role in fibrotic deposition 
and emphysematic alveoli destruction. 
Traditionally, COPD (specifically emphysema) and IPF are regarded as separate 
disease entities. Nonetheless, hallmarks of both COPD and IPF were first described in 
autopsies of lungs in 1974 (216); however, it was not until 2005 that this condition was 
classified as a well-defined syndrome termed CPFE (217). Male smokers or ex-smokers 
most often present with CPFE (217-219) and it has a dismal prognosis with only a 55% 
survival rate at 5 years (217). CPFE is a distinct under-recognized syndrome where no 
specific diagnostic guidelines are present, yet studies show that its presentation is much 
more frequent than previously believed (159). An important and highly fatal co-
morbidity in CPFE is the development of PH (220). The prevalence of PH in CPFE ranges 
between 47-90% and is much higher than in patients with IPF or emphysema alone (19, 
26, 28, 159). Confirmation of PH by right-heart catheterization data plummets 1-year 
survival rates to only 60% (26). Despite this dismal prognosis, no therapy options exist 
for patients with CPFE outside of smoking cessation, oxygen therapy and lung 
transplantation (27, 219). Specifically, for PH in CPFE, endothelin receptor antagonists, 
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prostanoids and phosphodiesterase type 5 inhibitors have been used. However, these 
agents are not recommended for PH in CPFE due to the vasodilation profile of these 
agents resulting in ventilation/perfusion mismatch (28), highlighting the need to 
develop novel treatment approaches for CPFE. 
Although several gene mutations have been associated with CPFE, including 
telomerase genes (hTERT or hTR), surfactant protein C (SFTPC) and ATP binding 
cassette subfamily A member 3 (ABCA3), these have been performed in very small 
familial cohorts (hTERT/hTR) or in case studies (SFTPC/ABCA3) (27). As such no single 
gene defect is known be associated with CPFE and the mechanisms leading to the 
development of CPFE remains vastly unknown (219). Despite this, studies in COPD and 
IPF patients with PH have revealed increased activation of the adenosinergic axis and 
enhanced levels of the glycosaminoglycan hyaluronan (158, 190, 221). In these studies, 
increased activation of the adenosine A2B receptor (ADORA2B) was shown to enhance 
expression of the hyaluronan synthases, contributing to the pathophysiology of chronic 
lung disease (158, 190, 221, 222).  Furthermore, several studies from our group, have 
implicated macrophages in the pathophysiology of lung fibrosis and PH. In these 
studies, deletion of myeloid ADORA2B was able to prevent BLM-induced PH and lung 
fibrosis (222). Further studies from our group have also demonstrated an important link 
between macrophage activation and ADORA2B expression promoting fibrotic lung 
injury (223). These results point at macrophages as a potential mechanism promoting 
lung fibrosis and PH, however whether they play a role in CPFE is not known.  
Using a unique model of experimental lung injury that replicates features of 
CPFE, namely airspace enlargement, PH and fibrotic deposition (158, 224), I investigated 
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the capacity of a hyaluronan synthase inhibitor to attenuate features of chronic lung 
injury and determined a link between hyaluronan expression and macrophages. 
 
Results 
Characterization of an experimental model of CPFE. 
I used Ada-/- mice to model features of CPFE. Ada-/- mice received supplemental 
PEG-ADA, allowing them to live normally, from birth up to week 24. Starting on week 
24, PEG-ADA was gradually reduced over 9 weeks and starting on week 34 mice were 
provided with control chow or medicated with 4MU for 4 weeks. The gradual reduction 
of PEG-ADA results in accumulation of extracellular adenosine that is associated with 
chronic injury (225). 
A hallmark of CPFE is the presence of fibrotic deposition and airspace 
enlargement. I determined the extent of fibrotic deposition first by staining lung 
sections with Masson’s Trichrome and performing Ashcroft scores to determine the 
extent of fibrosis. These experiments revealed a marked increase in fibrotic deposition 
in Ada-/- mice compared to Ada+ mice that was significantly attenuated in Ada-deficient 
mice treated with the hyaluronan inhibitor: 4-Methylumbelliferone (4MU) (Figure 25 
A, B). These histological changes were consistent with expression levels of fibronectin 
that were elevated in Ada-/- mice compared to Ada-competent mice. Therapy with 4MU 
reduced Fn expression levels in Ada-/- mice (Figure 25 C). I next examined the extent of 
airspace enlargement, a key feature of CPFE, in the mouse model using black and white 
images of the lung parenchyma. Ada-/- mice presented with evidence of airspace 
enlargement as observed histologically and by mean chord length measurements 
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determined morphometrically in comparison to Ada+ mice (Figure 25 D, E). Treatment 
with 4MU did not alter the emphysematous development in Ada-deficient mice (Figure 
25 D, E), despite improved arterial oxygenation (SpO2) compared to Ada-/- mice exposed 
to control chow (Figure 25F). The development of PH is a serious and common 
complication of CPFE (26). A feature of PH associated with chronic lung disease is 
vascular remodeling and hyaluronan deposition (158, 190, 226). In order to assess the 
extent of vascular remodeling, I performed dual-IHC for SMA and hyaluronan. These 
experiments revealed extensive muscularization of arterioles in Ada-/- compared to Ada+ 
mice that was significantly attenuated in 4MU-treated Ada-/- mice (Figure 25G). 
Widespread hyaluronan deposition was observed surrounding remodeled vessels in 
Ada-/- mice whereas no hyaluronan was present in parenchymal vessels of Ada-
competent animals; 4MU treatment drastically reduced the levels of peri-vascular 
hyaluronan in mice lacking ADA (Figure 25G). These observations were backed by 
morphometric evaluation of vascular wall remodeling and hyaluronan levels in BALF 
(Figure 25 H, I). These analyses demonstrated increased SMA signals in the remodeled 
vessels of Ada-/- mice compared to Ada+ mice that were attenuated in Ada-/- mice 
exposed to 4MU (Figure 25 H).  BALF hyaluronan levels revealed patently increased 
hyaluronan levels in Ada-/- compared to control mice that were markedly reduced in 
Ada-/- + 4MU exposed mice (Figure 25 I). Taken together, my results show that my model 
of Ada-/- mice presents with cardinal features of CPFE: fibrotic deposition, airspace 
enlargement and vascular remodeling, a key component of PH. Furthermore, I 
demonstrate that treatment of these mice with 4MU is able to attenuate both the 
fibrotic deposition and vascular remodeling in Ada-/- mice.  
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 (A) Representative Masson’s Trichome images showing fibrotic deposition in the in 
Ada-/- mice (middle panel) compared to Ada+ mice (upper panel). The effect of 4-MU in 
Figure 25 Features of chronic lung injury in Ada-/- mice and the effect of (4- 
methylumbelliferone [4-MU]) or control chow. 
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Ada-/- mice is shown in the bottom panel. Aschroft scores from Masson’s Trichome 
images (B) and mRNA expression levels of Fibronectin (FN, C) from Ada+(white bars), 
Ada-/- (grey bars) and Ada-/- + 4MU treated mice (black bars). (D) Black and white 
images of the lung parenchyma from Ada+ mice (upper panel), Ada-/- (middle panel) and 
Ada-/- + 4MU treated mice (lower panel). Mean chord length determined histologically 
(E) and arterial oxygen saturation (F) from Ada+ (white bars), Ada-/- (grey bars) and Ada-
/- + 4MU treated mice (black bars). (G) Representative dual-immunohistochemistry 
staining for alpha smooth muscle actin (SMA, blue signals) and hyaluronan (magenta 
signals) showcasing arterioles from Ada+ (upper panel) Ada-/- (middle panel) and Ada-
/- + 4MU (lower panel). Morphometric evaluation of SMA deposition from 5 to 7 vessels 
for each mouse (H) and broncho-alveolar lavage fluid (BALF) levels of hylauronan (I) 
from Ada+ (white bars), Ada-/- (grey bars) and Ada-/- +4MU treated mice (black bars). 
For panels B, C, E, F, H, I data is presented as mean + SEM. *P< 0.05 refers to 
comparisons between Ada+ and Ada-/- treatment groups. #< 0.05 refers to comparisons 
between Ada-/- and Ada-/- + 4MU treatment groups. Scale bars represent 200 µm 
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Vascular physiology, metabolism and hyaluronan levels in Ada-/- mice. 
Although vascular remodeling is a key feature of PH, right-heart catheterization 
and determination of RVSP in mice is necessary to adequately evaluate the extent of 
PH. As such, RVSP measurements were determined in my experimental model. I report 
increased RVSP in Ada-/- mice compared to Ada+ mice that were attenuated in Ada-/- + 
4MU mice (Figure 26A). Consistent with the phenomenon of PH, no differences in LVSP 
were observed between treatment groups (Figure 26B). The RVSP data was 
accompanied by evidence of right ventricle hypertrophy (RVH) in Ada-/- mice compared 
to Ada+ littermates that did not appear to be significantly attenuated following 4MU 
therapy (Figure 26C). In order to probe the mechanisms associated with the 
development of PH, I next evaluated the expression levels of the Adora2b and evidence 
of metabolic alterations. Enhanced adenosinergic axis and metabolic alterations have 
been reported in Group 3 PH (158, 190, 221, 222). These experiments revealed heightened 
Adora2b expression in Ada-/- mice but no expression in Ada+ or Ada-/- + 4MU mice 
(Figure 26D). Consistent with dysregulated metabolism, I report reduced levels of Pparg 
and Sdha that were not rescued following 4MU therapy (Figure 26 E, F). I next evaluated 
the expression levels of hyaluronan synthases, which are known to be up-regulated by 
ADORA2b activation. These experiments revealed elevated expression of Has3 but not 
Has1 or Has2 in Ada-/- mice compared to controls that was significantly reduced 
following 4MU treatment in Ada-deficient mice (Figure 26 G-I). Dual IHC for 
hyaluronan and αSMA revealed increased hyaluronan deposition in fibrotic areas in 
Ada-/- mice that was significantly attenuated following 4MU therapy (Figure 26J). These 
results demonstrate that Ada-/- mice present with physiological features of PH including 
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elevated RVSP and RVH in addition with increased Adora2b and Has3 expression, 
concomitant with elevated hyaluronic acid deposition observed histologically. 4MU 
therapy was able to attenuate the increased RVSP and hyaluronic acid deposition 
associated with reduced Adora2b and Has3 expression levels, but did not affect the 
dysregulated metabolic profile or reverse RVH. 
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Right ventricular systolic pressure (RVSP, A), left ventricular systolic pressure (LVSP, B) 
and Fulton Index ratio (C) determined by the measure of right ventricle and left 
ventricle with septum from Ada+ (white bars), Ada-/- (grey bars) and Ada-/- +4MU treated 
Figure 26 Cardiovascular physiology, metabolic profile and hyaluronan 
synthesis and deposition in Ada-/- . 
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mice (black bars). Transcript expression levels from lung tissue for Adora2b (D), Pparg 
(E), Sdha (F), Has1 (G), Has 2 (H), Has 3 (I) by RT-PCR from Ada+ (white bars), Ada-/- 
(grey bars) and Ada-/- +4MU treated mice (black bars). (J) Representative dual-
immunohistochemistry staining in fibrotic areas of Ada-/- or Ada-/- + 4MU treatment 
groups for alpha smooth muscle actin (SMA, blue signals) and hyaluronan (magenta 
signals). Scale bars represent 200 µm. For panels A-I data is presented as mean + SEM. 
*P< 0.05 refers to comparisons between Ada+ and Ada-/- treatment groups. #< 0.05 refers 
to comparisons between Ada-/- and Ada-/- + 4-MU treatment groups. The N used for 
these studies are 8 (Ada+); 13 (Ada-/-); 5 (Ada-/- +4MU). Variations in N are due to 
violation of a predetermined criteria: heart rate below 250 BPM at the time of RVSP or 
LVSP. 
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Macrophages in Ada-/- mice. 
An interesting feature of the Ada-/- mice was the presence of F4/80 positive cells 
in the lung (Figure 27A), while treatment with 4MU resulted in an attenuation of F4/80+ 
cells in Ada-/- mice (Figure 27A, B). I next evaluated whether these cells were positive for 
HAS3. Indeed, double-IHC for HAS3 and F4/80 revealed signals for HAS3 and F4/80 in 
Ada-/- mice that appeared reduced following treatment with 4MU (Figure 27 C, D). 
Interestingly, increased HAS3 signals were observed in vascular and epithelial cells.  
Further IHC demonstrated that these HAS3-positive cells also expressed hyaluronan 
and were observed close to vessels in Ada-/- mice (Figure 28 A). Treatment with 4MU 
resulted in an attenuation of HAS3/hyaluronan positive cells and a marked reduction of 
hyaluronan (Figure 28 A, B). These HAS3+ cells were also observed in areas rich in 
myofibroblasts (observed using αSMA IF) that were reduced following 4MU treatment 
(Figure 28 C, D). Our group has previously demonstrated that activation of hypoxic 
adenosinergic axis in macrophages is important for the development of lung fibrosis 
(222, 223). In these studies, reduced hyaluronan deposition was observed in mice 
lacking Adora2b in myeloid cells (222). Thus, using MH-S cells, a murine macrophage 
cell line, I next examined whether increased expression of the hyaluronan synthase 
isozymes was Adora2b-dependent. These experiments revealed that Has2 and Has3, but 
not Has1, was increased following treatment with the ADORA2b agonist Bay60-6583, 
and that this response was inhibited by the presence of the ADORA2b antagonist GS-
6201 (Figure 29 A-C). This response was consistent with elevated BAY60-6583-induced 
interleukin-6 that was inhibited by GS-6201 (Figure 29 D). IL-6 is a known pro-fibrotic 
mediator downstream of macrophage ADORA2b stimulation (222, 223, 227). Taken 
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together, these results point at an ADORA2b-mediated increase of HAS3-expressing 
macrophages (F4/80 positive cells) that lead to increased hyaluronan deposition.  
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(A) Immunohistochemistry for F4/80 (yellow signals) and nuclear DAPI stain showing 
F4/80 positive cells in Ada+ (upper panel) Ada-/- (middle panel) and Ada-/- + 4MU (lower 
panel). Scale bar represents 75 µm. (B) F4/80 positive cells from 10 micropictographs 
from the lung parenchyma from Ada+ (white bars), Ada-/- (grey bars) and Ada-/- + 4MU 
treated mice (black bars). *P< 0.05 refers to comparisons between Ada+ and Ada-/- 
Figure 27 Macrophages in Ada-/- mice. 
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treatment groups. #< 0.05 refers to comparisons between Ada-/- and Ada-/- + 4MU 
treatment groups. (C) Dual immunohistochemistry for hyaluronan synthase 3 (Has3, 
red/brown signals) and F4/80 (blue signals) in Ada+ (upper panel) Ada-/- (middle panel) 
and Ada-/- + 4MU (lower panel). Scale bar represents 200 µm. (D) Double F4/80 and 
HAS3 positive cells from 10 micropictographs from the lung parenchyma from Ada+ 
(white bars), Ada-/- (grey bars) and Ada-/- + 4MU treated mice (black bars). *P< 0.05 
refers to comparisons between Ada+ and Ada-/- treatment groups. #< 0.05 refers to 
comparisons between Ada-/- and Ada-/- + 4-MU treatment groups 
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 (A) Dual immunohistochemistry for hyaluronan synthase 3 (Has3, magenta signals) 
and hyaluronan (blue signals) in Ada-/- (upper panels) and Ada-/- + 4MU (lower panels). 
Scale bar represents 100 µm. (B) Double HAS3 and hyaluronan positive cells from 10 
micropictographs from the lung parenchyma from Ada-/- (grey bars) and Ada-/- + 4MU 
treated mice (black bars). (C) Dual immunohistochemistry for hyaluronan synthase 3 
(Has3, magenta signals) and alpha-smooth muscle actin (SMA green signals) in Ada-/- 
(upper panels) and Ada-/- + 4MU (lower panels). Scale bar represents 75 µm. (D) Double 
HAS3 and SMA positive cells from 10 micropictographs from the lung parenchyma from 
Ada-/- (grey bars) and Ada-/- + 4MU treated mice (black bars). #< 0.05 refers to 
comparisons between Ada-/- and Ada-/- + 4-MU treatment groups  
Figure 28 Macrophages in Ada-/- mice express HAS3. 
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Experimental Design Mertens TCJ, Collum SD, Karmouty-Quintana H. Experiment 
performed by and experimental data compliments of Mertens TCJ.  
 
Transcript levels of (A)Has1, (B) Has2, (C) Has3, (D) IL6 of MH-S cells exposed to DMSO 
(black bars); the Adora2b antagonist: GS-2601 (grey bars), the Adora2b agonist: BAY60-
6583 (blue bars), or under the presence of both GS-2601 and BAY60-6583 (red bars). *P< 
Figure 29 Response to macrophages to an ADORA2B agonist. 
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0.05 refers to comparisons between DMSO and BAY60-6583 treatment groups. #< 0.05 
refers to comparisons between BAY60-6583 and BAY60-6583 + GS-2601 treatment 
groups.  
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The adenosinergic response in CPFE. 
Using explanted lung tissue derived from upper or lower lung lobes from CPFE 
patients or from normal lungs that were discarded for transplantation, I evaluated 
mediators involved in the generation and degradation of adenosine, in addition to 
adenosine receptors. In CPFE, upper lobes often present with emphysema while fibrotic 
deposition is more prevalent in lower lobes. Quantitative RT-PCR for the 
ectonucleotidases CD39 and CD73 (Figure 30 A, B) demonstrated increased expression 
of the rate limiting enzyme CD73 but not CD39 in lower lobes but not upper lobes of 
CPFE compared to normal lung tissue (Figure 30 A, B). No differences were seen in ADA 
expression levels from lung tissue derived from upper or lower lobes (Figure 30 C). 
Equilibrative nucleoside transporters (ENT) also regulate extracellular adenosine levels 
whereby reduced expression is associated with increased adenosine accumulation and 
the development of lung injury (228).  However, I report no difference in ENT 
expression in CPFE despite a downward trend for ENT-2 in lower lobes of CPFE lungs 
(Figure 30D). Expression levels of adenosine receptors did not show significant 
alterations in ADORA1 or ADORA2A between normal and CPFE lung tissue (Figure 30 
E, F). However, increased expression levels of ADORA2B were detected in lower lobes 
of CPFE compared to normal lungs but not in tissue derived from upper lobes (Figure 
30 G). Similarly, to ADORA1 and ADORA2A, no significant differences in expression of 
ADORA3 were observed between normal and CPFE-derived lung tissue (Figure 30 H). 
Taken together, these results suggest that in CPFE, like in other chronic lung 
diseases(225), increased adenosine synthesis is enhanced in concert with expression of 
its low-affinity receptor, ADORA2B. 
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Lung transcript levels for (A) CD39, (B) CD73, (C) ADA, (D) ENT2, (E) ADORA1, (F) 
ADORA2A, (G) ADORA2B, (H) ADORA3; from upper lobes from normal lungs (white 
bars), upper lobes from CPFE lungs (light blue bars), lower lobes from normal lungs 
(grey bars), and lower lobes from CPFE lungs (dark blue bars). *P< 0.05 refers to 
comparisons between normal and CPFE groups within upper or lower lung lobes. 
  
Figure 30 The adenosinergic response in CPFE. 
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The extra-cellular matrix in CPFE. 
Next, I evaluated the protein levels of ADORA2B and HAS3 in CPFE. Protein 
expression levels for ADORA2B revealed increased expression in lower lobes from CPFE 
lung tissue vs normal controls, concomitant with increased signals for HAS3 (Figure 31 
A-C). These observations were in-line with IHC for αSMA, revealing hyaluronan signals 
in highly remodeled areas of lung characterized by dense myofibroblast presence and 
prominent vascular remodeling in CPFE lungs compared to normal tissue (Figure 31 D). 
Similarly, staining for HAS3 and CD68 (a human monocytic phagocyte marker) revealed 
positive signals for CD68 and HAS3 in lower lobes of CPFE lungs (Figure 31 E, F). These 
results did not show alterations in HAS1 or HAS2 between normal and CPFE lung tissue 
derived from upper or lower lobes (Figure 32 A, B). Gene expression for fibrotic genes 
revealed increased expression of FN1 in upper lobes of CPFE vs normal lungs but not in 
lower lobes (Figure 32 C). Expression levels of COL1A1 revealed significantly increased 
expression levels in lung tissue derived from lower lobes from CPFE vs normal lung 
tissue (Figure 32 D). COL1A2 was significantly elevated in both upper and lower lobes 
in CPFE vs normal lung tissue, whereas COL2A1 was elevated only in the lower lobes 
from CPFE lungs (Figure 32 E, F). These collagens have previously been shown to 
express in the lung and be associated with lung disease (73, 158, 229). Interestingly, these 
results demonstrate that purinergic remodeling and increased ADORA2B levels in CPFE 
are observed in the lower lobes were fibrotic deposition is most evident and in areas of 
vascular remodeling, in line with the role of adenosine in promoting fibrotic deposition 
and vascular remodeling in chronic lung injury (225).   
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Western blot for ADORA2B, HAS3 and GAPDH from upper and lower lobes from 
normal or CPFE lungs (A). Densitometries for ADORA2B (B) and HAS3 (C) from upper 
lobes from normal lungs (white bars), upper lobes from CPFE lungs (light blue bars), 
lower lobes from normal lungs (grey bars), and lower lobes from CPFE lungs (dark blue 
bars). (D) Dual immunohistochemistry for alpha smooth muscle actin (SMA, red/brown 
Figure 31 ADORA2B and HAS3 are elevated in CPFE. 
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signals) and hyaluronan (blue signals) in normal (upper panels) or CPFE (lower panels) 
lungs. The red V denotes vessels and the green asterisks point at myofibroblasts. (E) 
Immunohistochemistry for CD68 (blue signals) and HAS3 (red signals) from lower lobes 
from normal and CPFE lungs. Red arrows represent CD68 positive (HAS3 negative) 
signals. Black arrows point at dual HAS3 and CD68 signals, scale bar represents 50 µm. 
(F) Double HAS3 and CD68 positive cells from 10 micropictographs from the upper 
lobes from normal lungs (white bars), upper lobes from CPFE lungs (light blue bars), 
lower lobes from normal lungs (grey bars), and lower lobes from CPFE lungs (dark blue 
bars). *P< 0.05 refers to comparisons between normal and CPFE groups within upper or 
lower lung lobes.  
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Transcript levels for (A) HAS1, (B) HAS2, (C) FN1, (D) COL1A1, (E) COL1A2, (F) COL2A 
from upper lobes from normal lungs (white bars), upper lobes from CPFE lungs (light 
blue bars), lower lobes from normal lungs (grey bars), and lower lobes from CPFE lungs 
(dark blue bars). *P< 0.05 refers to comparisons between normal and CPFE groups 
within upper or lower lung lobes. 
  
Figure 32 Extracellular matrix signals in CPFE. 
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Discussion 
Despite reductions in mortality in cancer and cardiovascular disease, mortality 
rates for chronic lung diseases including interstitial lung disease have remained 
unaffected over the last decade(230). This is a direct result of disparate funding 
allocated towards research in chronic lung disease that in no way reflects the heavy 
societal burden of the disease (230). This translates to an overwhelming lack of effective 
therapies for chronic lung diseases. CPFE represents a chronic lung disease syndrome 
that has higher mortality and morbidity rates than diseases such as COPD or IPF. Like 
other chronic lung diseases, limited therapeutic options exist outside lung 
transplantation (27, 218, 219). Thus, there is a need to identify novel treatments that can 
attenuate features of CPFE and improve the morbidity and mortality rates. In this study, 
I have characterized an experimental model of CPFE using male 6-month-old Ada-/- 
mice and demonstrated that they present with features of CPFE, namely fibrotic 
deposition, airspace enlargement and PH. I have also generated preliminary results that 
show that 4MU, also known as hymecromone, an FDA-approved drug, is capable of 
attenuating fibrotic deposition and PH in a murine experimental model of chronic lung 
injury that recapitulates features of CPFE. Furthermore, my studies utilizing lung 
tissues derived from upper or lower lobes from explanted lungs from patients with CPFE 
or from normal lungs that were discarded for transplantation, reveal an upregulated 
adenosinergic response and evidence of increased hyaluronic acid deposition. 
Evaluation of the potential mechanisms leading to increased hyaluronan in the 
experimental model point at Adora2b-mediated Has3 expression in macrophages that 
is supported by dual F4/80 and Has3 positive cells observed histologically. 
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There is a lack of experimental models of lung disease that can accurately 
recapitulate the pathophysiology of chronic lung diseases (231). This is particularly the 
case for CPFE, where limited animal models that recapitulate its cardinal features 
(fibrotic deposition, airspace enlargement and PH) have been described. Features of 
CPFE have been modeled by treating mice with both the fibrotic agent bleomycin and 
elastase to induce airspace enlargement (232, 233). Experiments have also been 
performed treating cigarette-smoke exposed mice with the pro-fibrotic agents 
bleomycin or herpesvirus leading to airspace enlargement and fibrotic matrix 
deposition (234). Additionally, exposure to the halogen gas bromine (Br2) has also been 
shown to induce combined airway fibrosis and emphysema (235). Although these 
models are able to recapitulate features of CPFE, they rely on chemical-induced lung 
injury, which does not accurately represent the etiology of CPFE (219). Furthermore, 
these models have not characterized the presence of PH, an important feature of CPFE 
(19, 26, 28, 159). 
The Ada-/- mouse model of lung injury was first reported by Blackburn et al.(236, 
237)  and has demonstrated to recapitulate important features of chronic lung injury 
such as fibrotic deposition, airspace enlargement and PH (158, 238, 239). In these studies 
both male and female littermate Ada-/- and Ada+ mice were utilized and PEG-ADA 
therapy was maintained typically up to post-natal day 21 whereupon it was 
discontinued, leading to a rapid increase in extracellular adenosine levels resulting in 
lung injury observed typically 15 to 20 days after cessation of PEG-ADA therapy (158, 
238, 239). To adequately model CPFE, a disease that primarily affects males (217-219), I 
utilized male 6-month old Ada-/- mice that were subjected to a progressive reduction in 
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PEG-ADA therapy leading to a gradual increase in extracellular adenosine. Using this 
approach, I aimed to mimic the repeated subclinical injury that is associated with 
chronic lung diseases. Using this approach, mice presented with extensive remodeling 
of the lung parenchyma including airspace enlargement, fibrotic deposition and 
vascular remodeling and PH consistent with previous publications(158, 238, 239). 
However, the extent of fibrotic injury and features of PH, such as RVSP, appeared 
enhanced in the model of gradual reduction of PEG-ADA therapy using male mice. 
An important therapeutic finding from my study was that 4MU was capable of 
inhibiting PH in the Ada-/- mice, consistent with previous studies using bleomycin-
exposed mice that presented with fibrotic deposition and PH (226). However, contrary 
to the study of Collum et al (226), this study demonstrates that 4MU is capable of 
attenuating the fibrotic deposition in Ada-/- mice. This discrepancy could be explained 
by the different treatment regimen of 4MU. In the present study, 4MU was 
administered for 4 weeks whereas in the previous study it was only given for 2 weeks 
(226). Thus the longer treatment regimen may explain the effect of 4MU at inhibiting 
both PH and fibrotic deposition; this effect is supported by a greater reduction of 
hyaluronan levels, observed by ELISA in BALF, in the present study using Ada-/- mice 
compared to previous studies in the bleomycin model of lung fibrosis (226). These are 
important pre-clinical results demonstrating that an FDA-approved drug has the 
capacity of attenuating cardinal features of CPFE, a disease that currently lacks any 
effective therapy outside lung transplantation (27, 219). 
Consistent with previous publications from our group(158, 190), I demonstrate 
that both elevated Adora2b expression and hyaluronan accumulation are present in the 
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experimental model of lung injury. A novel finding of this study was that Has3, but not 
Has1 or Has2 as in previously reported in models of lung injury (158, 190, 226), was the 
main hyaluronan synthase that was upregulated in the experimental model. My results 
are consistent with cigarette-exposed mice where increased lung hyaluronan and Has3 
expression was observed (240). Interestingly, elevated Has3 signals were primarily 
observed in macrophages in Ada-/- mice. In addition, increased Has3 expression in 
macrophages was Adora2b-dependent, consistent with previous publications utilizing 
mice lacking Adora2b-expression in the monocyte lineage (222) and from studies 
demonstrating an Adora2b-dependent Has expression in pulmonary artery smooth 
muscle cells (190, 226). Treatment with 4MU was able to attenuate Has3 expression 
levels consistent with reduced hyaluronan accumulation and macrophages. These 
results point at macrophages as an important contributor to the development of lung 
fibrosis and PH, consistent with prior studies (222, 223, 241, 242) where alternatively-
activated macrophages were shown to promote the development of features of chronic 
lung injury. It is important to mention that increased Has3 signals were also observed 
in epithelial and vascular cells in Ada-/- mice that could also contribute to increased 
hyaluronan accumulation. Increased vascular or peri-vascular expression of Has3 and 
subsequent hyaluronan deposition could also contribute directly to vascular 
remodeling and PH by promoting vascular stiffness and proliferation as demonstrated 
previously by our group (226). Pulmonary artery smooth muscle cell expression of 
hyaluronan synthases has been shown to be modulated by activation of Adora2b (55, 
190). This is in line with studies showing Adora2b-mediated macrophage Has3 
expression.  
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A novel finding of this study was that Has3-expessing macrophages appeared to 
contribute to chronic lung injury. This is significant, as typically Has3 is associated with 
the generation of low-molecular-weight (LMW) hyaluronan fragments (243). These 
LMW hyaluronan fragments are associated with pathogenic effects (189, 240). 
Importantly, results from the experimental model were consistent with the presence of 
HAS3-expressing CD68 cells in CPFE that was consistent with massive hyaluronan 
deposition surrounding fibrotic areas and remodeled vessels from CPFE explanted 
lungs. These results are highly significant since little is known regarding the pathogenic 
mediators involved in the pathophysiology of CPFE.  
It is important to mention that adenosine is a danger-associated molecular 
pattern that is generated following cell injury and subsequent extracellular release of 
ATP that is converted to adenosine by CD39 and CD73, with the latter being the rate-
limiting enzyme (244). Adenosine can then activate any of its four receptors: ADORA1, 
ADORA2A, ADORA2B and ADORA3 (245).  Adenosine is known to have many 
protective effects acutely, however chronically elevated levels of adenosine and 
subsequent activation of its low-affinity receptor, ADORA2B, has been extensively 
associated with chronic lung injury (225). An important phenomenon that promotes 
adenosine accumulation is purinergic remodeling, a phenomenon characterized by 
increased expression of the ectonucleotidase CD73 and reduced ADA and ENTs that 
collectively promote extracellular adenosine accumulation and subsequent ADORA2B 
activation (246). This phenomenon has been shown to be present in chronic lung 
diseases such as COPD and IPF (247), and my data from CPFE explanted lung tissue 
reveals evidence of purinergic remodeling consistent with increased ADORA2B 
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expression.  Taken together, these observations advocate the use of an ADORA2B 
antagonist to treat chronic lung diseases. Indeed, preclinical studies using both Ada-/- 
and bleomycin-treated mice have demonstrated that genetic or pharmacological 
abrogation of Adora2b signaling is capable of attenuating features of chronic lung injury 
(158, 190, 239, 248). 
Unexpectedly, treatment with 4MU was not able to attenuate airspace 
enlargement, RVH or metabolic changes in Ada-/- mice. RVH is typically a response to 
increased RVSP, as such it is conceivable for changes to be observed over time following 
normalization of blood pressure. Airspace enlargement may however be due to other 
adenosinergic mechanisms promoting alveolar cell destruction. These potential 
mechanisms may include elevations in deoxy-adenosine a molecule that is also 
metabolized by ADA and accumulates in Ada-/- mice (249). Increased phosphorylation 
of deoxy-adenosine by deoxy-cytosine kinase has been shown to contribute to airspace 
enlargement in Ada-/- mice and increased deoxy-cytosine kinase signals have been 
detected in stage 4 COPD (249). Taken together, these studies suggest that treatment 
of 4MU may not alter deoxy-cytosine kinase or deoxy-adenosine levels to alter airspace 
enlargement. Similarly, alterations in metabolism have also been reported in Ada-/- mice 
(237) that may not be affected by 4MU, but this compound may be effective at treating 
lung fibrosis and PH in CPFE.  
In conclusion, my study has demonstrated that a gradual reduction of PEG-ADA 
to male 6-month-old Ada-/- mice results in the development of hallmarks of CPFE: 
airspace enlargement, fibrotic deposition and PH. In addition, I demonstrate using a 
therapeutic approach that the FDA-approved drug, 4MU, is capable of reducing the 
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extent of fibrotic injury and features of PH. My study also proposes a novel mechanism 
whereby Has3-positive macrophages contribute to chronic lung injury in Ada-/- mice. 
Importantly, observations in the experimental model of CPFE were recapitulated in lung 
explants from patients with CPFE, where increased hyaluronan was detected in 
remodeled areas of the lung consistent with HAS3 expressing CD68-positive cells. These 
results are significant since very little is known regarding the mechanisms that promote 
injury in CPFE and as a result limited therapies exist for this deadly condition. My study 
proposes that inhibition of hyaluronan accumulation is as a novel potential therapy for 
CPFE. 
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Chapter 6: Conclusions and Future Directions 
Conclusions 
The work presented here contributes to our understanding of the molecular 
changes involved in vascular remodeling and PH. My work has identified a role for 
NUDT21 in the pathogenesis of PH. Specifically, I demonstrate that NUDT21 depletion 
is present in remodeled vessels of patients with either Group 1 or Group 3 PH and that 
NUDT21 depleted PASMCs undergo a phenotypic switch that promotes vascular 
remodeling. There were also large gaps in the knowledge about the role of HA in 
contributing to vascular remodeling in Group 1 or Group 3 PH. While HA and HA 
related enzymes had been shown to be associated with PH, the mechanism had not 
been fully explored. I describe two pathways through which changes in HA deposition 
in the lung contribute to disease.  
 The results in Chapter 3 describe a novel mechanism for changes in PASMCs 
during PH development through regulation of RNA maturation. While NUDT21 
mediated APA has been described in several disease states to this point, it has not been 
shown in PASMCs or in PH. These changes observed in the PASMCs are consistent with 
changes seen in the literature in PH. Interestingly, NUDT21 deletion in PASMCs leads 
to increased RVSP in the absence of hypoxia-sugen model. This finding together with 
the fact that over-expression of NUDT21 in PASMCs from patients restores them to a 
proliferative phenotype similar to cells from healthy donors indicates that NUDT21 is a 
key regulator of vascular remodeling and PH. This new mechanism adds to our current 
knowledge of the pathways that drive vascular remodeling and PH. 
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 The results in Chapter 4 describe the role and mechanism of HAS2 in PASMCs. 
Here I describe the role of HA in the development of PH, showing that, 4MU, an 
inhibitor of HA production, inhibited RVSP in two models of PH. I additionally showed 
that deletion of HAS2 from the PASMCs of mice is also protective from PH. While 
previous studies have shown an association between increased HA and chronic lung 
disease, my research was the first to identify a causative role of HA. This research is also 
the first to use pharmacological inhibition of HA production to treat PH. This finding 
is exciting in that it identifies a potential therapy for this disease. Not only did I describe 
the role of HA in PH, I also identified one of the pathways through which these cellular 
changes are produced. Using the Rho-kinase inhibitor fasudil allowed me to describe 
the RhoA/ROCK signaling pathway as the signaling pathway through which HA signals 
in these cells.  
 The results in Chapter 5 describe the role of HA in CPFE, a relatively recently 
defined disease. As a recently classified disease, few mechanistic studies have been 
performed to understand the initiation and development of CPFE. Previous work in the 
lab has described the role of ADORA2B in regulating HA production in chronic lung 
diseases but did not describe mechanism or look at CPFE. In this work I first studied 
the ADA deficient mouse and discovered a novel model for CPFE, including the 
combined fibrotic deposition and destruction of the alveoli and associate PH. As 
ADORA2B expression and HA were upregulated in this model I then were able to 
describe the use of 4MU in treatment of the fibrotic deposition and PH symptoms in 
this mouse model. This also revealed that the emphysematic portion of this disease may 
be caused by adenosinergic signaling but it is not associated with HA. I also describe a 
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group of HAS3 expressing macrophages that is found in association with both the mouse 
model of CPFE and patient samples of CPFE.  
Given the complex cellular interaction in the lung and equally complex 
intracellular regulation of pulmonary cells it is difficult to discover the mechanisms that 
contribute to chronic lung diseases. Here I describe two mechanisms involved in the 
progression of PH and one of the first mechanisms described for the progression of 
CPFE. This advance in knowledge is important in the continued struggle to understand 
these chronic and progressive diseases, and will provide novel opportunities for 
continued research and therapeutic research.  
 
Future Directions 
NUDT21 in other chronic lung diseases 
The most direct next step that is indicated by the research here as well and previously 
published studies is to identify the role of NUDT21 depletion in other chronic lung 
diseases. One of the first to be investigated should be CPFE. The role of NUDT21 
mediated APA has been shown in fibroblast in IPF and this thesis has shown this process 
is important in PH. Additionally, preliminary data here shows NUDT21 depletion in 
COPD lung tissue (Figure 33). Taken together, these data strongly support a role for this 
mechanism in the pathogenesis of CPFE as it is important in key malignant processes, 
fibrosis and emphysema, as well as the often-associated PH.  
 To characterize the role of NUDT21 mediated APA in CPFE a two-pronged 
approach should be taken. Human CPFE tissue should be analyzed for NUDT21 changes 
by western blot, and then RT-PCR should be utilized to test for APA events in the genes 
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most well characterized to shorten such as VMA21. At the same time tissue from the 
ADA deficient mouse model of CPFE should be analyzed in the same manner.  
To identify the APA targets important to this disease, it is likely that analysis of 
whole tissue will be confounded by APA events that differ between cell types. To 
mitigate this, cells should be isolated from either patients or the mouse model and 
then analyzed for APA changes against healthy controls. The cell types to be analyzed 
should be fibroblasts, PASMCs, and alveolar epithelial type 2 cells which undergo 
apoptosis in COPD (250). Identifying this mechanism as important in CPFE would add 
additional knowledge to this poorly understood and complex disease.  
 
Western blot for NUDT21 and GAPDH in Normal and COPD patient lung samples. 
 
 
What other genes are shortened by NUDT21 depletion in PH. 
As discussed in Chapter 1 several key changes happen to PASMCs during vascular 
remodeling. My results show that NUDT21 depletion plays a role in modulating the 
proliferative and migratory capacity of PASMCs. While shortening and increased 
expression of HAS2 mRNA plays a role in this change, other genes are also involved. 
The DaPars algorithm identified 664 shortened genes in the NUDT21 knock down in 
Figure 33 Reduced NUDT21 Levels in COPD 
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PASMCs. The data from this algorithm identified RUNX1 as one of the most shortened 
targets of NUDT21 depletion. This shortening was also associated with increased reads 
indicating increased mRNA levels. RUNX1 is a poorly described transcription factor 
known to be expressed in hematopoietic stems cells and plays an important role in 
controlling proliferation and self-renewal (251). Additionally mutations in this gene 
contribute to a wide variety of leukemia types (252). RUNX2 along with a common 
cofactor with RUNX1, CBFβ, has been implicated in proliferation of PASMCs and 
remodeling in PH (253). As shortening of RUNX1 lead to aberrant expression in the 
NUDT21 knock down, and RUNX1 is a strong driver of disease states, investigating the 
role of this shortening in PH is encouraging. 
To identify if RUNX1 3’UTR shortening is an important downstream effect of NUDT21 
depletion several studies need to be performed. First RUNX1 shortening in PAH patient 
samples should be confirmed by DaPars analysis of RNA-seq data. This should also be 
determined by RT-PCR experiments to show dPAS usage. After this APA event has been 
confirmed in human samples of disease, a mechanistic link should be determined. In 
vitro it should be shown that RUNX1 is necessary for NUDT21 mediated changes in 
PASMCs phenotype by knocking down NUDT21 with siRNA and then treating the cells 
with 2-pyridyl benzimidazole AI-4-57, a RUNX1-CFBβ inhibitor. If the phenotype of 
these cells differs from controls with only NUDT21 a mechanistic link will be confirmed. 
In the event that inhibitor is toxic to these cells I can use siRNA to knockdown RUNX1 
as well. It will also be confirmed that RUNX1 is shortened in the PASMCs of C57B/6 
mice and NUDT21f/+TaglnCre mice in the hypoxia-sugen model. The same inhibitor can 
be used to treat these mice to determine if blocking RUNX1 induced by NUDT21 
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mediated APA is a therapeutic option in PH. Continued studies could identify 
aberrantly expressed genes activated by RUNX1 binding. Identifying the pathways that 
lead to proliferation in NUDT21 downregulation will likely identify pathways key for PH 
development. 
 
Targeting NUDT21 depletion mediated APA therapeutically.  
While NUDT21 depletion appears to be sufficient to induce phenotypic changes in 
PASMCs, it is not evident what mechanisms control these levels during the initiation of 
PH. In order to target this mechanism therapeutically it is important to know what 
regulated NUDT21 levels. It is known that several miRNAs including miRNA-181a target 
NUDT21. In fact miRNA181a appears to drive a NUDT21 depletion dependent increase 
in proliferation in osteosarcoma (116). To determine if miRNAs control the level of 
NUDT21 in PASMCs during PH the transcript sequence of NUDT21 should be analyzed 
by a tool such as TargetScanHuman 7.2. The miRNA hits that this tool predicts should 
then be cross-referenced against miRNAs known to be induced during PH (254). The 
miRNAs in both sets should then be investigated using a dual luciferase vector with the 
NUDT21 3’UTR as the target sequence. Identification of one or more miRNAs that are 
upregulated in PH and that strongly downregulate NUDT21 in this assay would provide 
strong evidence that this is the mechanism of control. It is also possible that other 
pathways contribute to changes in NUDT21 levels. Investigating the transcription 
factors and enhancers that activate NUDT21 expression would require more in-depth 
studies but could provide interesting insights. 
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An additional area of potential therapeutics is the CFIm complex as a whole. My 
research focused on the role of NUDT21 on PH but I did show reduced levels of CFIm59 
and CFIm68 in several disease states. These decreases were not as consistent as with 
NUDT21 but could be as important for some roles of CFIm. As discussed previously 
NUDT21 likely acts in concert with its partners by binding two of the same protein in 
quaternary complex (255). If these other partners provide some specificity in controlling 
cleavage and polyadenylation, it is possible that targeting only one of CFIm59 or 
CFIm68 would provide more targeted changes in PASMCs without effecting APA in 
such a global scale, which may have unintended effects. To investigate this, PASMCs in 
culture should be depleted of either CFIm59 or CFIm68 and then proliferative and 
migratory outcomes can be observed. If these changes are similar to that seen in 
NUDT21 depletion, then a study of the APA landscape can begin, first with RT-PCR of 
known regulators seen in the NUDT21 studies and eventually with RNA-seq to 
understand how the APA landscape differs. The eventual goal would be to identify a 
target interaction key to PH associated APA but not necessary for steady state cleavage 
and polyadenylation that could be used as a target to screen compounds that would 
simply interrupt that one interaction.  
 
 4MU as a therapy for PH in patients 
Undoubtedly the most significant and daunting next steps implicated by the findings 
here is that of testing 4MU in patients with PH. 4MU is an approved therapy for biliary 
dyskinesia in some countries under the name hymecromone. In the clinical trials for 
this use no severe side effects were seen and treatment by oral delivery is effective. 
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Unfortunately the pharmacology is not ideal for treatments, as 4MU is quickly 
metabolized and excreted from the body (256). This drug has also not been tested in a 
chronic treatment scenario with on label usage only for acute biliary spasms and a single 
trial showing relative safety for three months of treatment (257). Despite this, my 
findings support using this drug for patients with PH. This drug is also a potential target 
for cancer research as in vitro studies have shown that 4-MU treatment reduces cancer 
metastasis (258). In a mouse model with implanted cancer cells, 4MU treatment 
reduced tumor size (259).  As there is no curative treatment and PH is progressive any 
treatment that could provide distinct benefits should be investigated, especially one 
with few side effects that has been used to treat other disease.  
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Appendix: Materials and Methods 
 
Scientific Rigor 
All analyses were blinded to the experimenter. A two-way analysis of variance (ANOVA) 
with the Bonferroni correction was performed for all experiments with more than 2 
groups. For experiments that consisted of two groups, an un-paired two-tailed Students 
t-test. The Grubbs' test was used to detect outliers. GraphPad Prism 7.0 or higher was 
used to analyze the data. All software used in this study is available commercially. 
Sex as a biological variable 
In experiments using IP BLM, male mice were utilized, as IPF is more prevalent in males 
than in females (260-262). Male mice also have a greater response to BLM than female 
mice irrespective of age (263). In the hypoxia-sugen model both male and female mice 
are used and no difference in symptoms or histology is observed. As CPFE is ~20 times 
more prevalent in males than females, the chronic ADA deficient mouse model utilizes 
only males of six months of age (264).  
As IPF is much more prevalent in males, male patients dominated the samples of this 
diagnosis though a more even sex distribution is available for patients with IPF+PH. 
PAH is 2-4 times more prevalent is females and this is evident in the available samples 
(5). CPFE patient samples were only collected from males as the disease is almost 
exclusively male and the disease was only recently described. As healthy lungs are 
typically only explanted for potential transplantation, it is uncommon to receive healthy 
tissue from age matched controls.  
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Human subjects 
The use of human material for this study was reviewed by the University of Texas Health 
Science Center at Houston Committee for the Protection of Human Subjects 
(Institutional Review Board no. HSC-MS-08-0354). The demographic details of the 
study population are summarized in Table 1. De-identified lung explant tissue from 
patients with IPF and corresponding de-identified clinical parameters were obtained 
from the Methodist Hospital (Houston, TX). IPF was diagnosed by board-certified 
pulmonologists upon admittance for lung transplantation at the Houston Methodist 
Hospital. Pulmonary hypertension was defined as a mean pulmonary pressure ≥ 25 
mmHg and a pulmonary capillary wedge pressure ≤ 15 mmHg; the hemodynamic 
measurements were obtained from the right heart catheterization performed as part of 
the transplant evaluation. Control lung tissue was obtained from lungs that were 
declined for transplantation but had no pulmonary chronic disease or contusion. 
Healthy control lung tissue was obtained from the International Institute for the 
Advancement of Medicine (Edison, NJ). 
Tissue was collected at the time of lung explantation and processed on site within 20 
min. The lobes were identified from each lung explant, and for each lobe, the center was 
identified, taking the airway as a reference point. A 1 cm transverse center cut was 
performed to obtain a section from the center of each lobe. Consequently, this tissue 
was divided into three sections to separate external (closest to pleura), center and 
internal (closest to bronchi) portion according to the airway. A piece from each portion 
was then cut for histology, and an adjacent section was flash frozen in liquid nitrogen. 
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 IPF (n=10) IPF + PH(n=9) PAH(n=6) CPFE(n=4) Healthy(n=8) 
Female 2/10 4/9 5/6 0/4 5/10 
Males 8/10 5/9 1/6 4/4 5/10 
Age 63.4±2.9 57.3±4.6 47.5±13.1 60.4±7.0 41.1±14.3 
mPAP 20.0±1.7 31.3±1.5 48±9.6 24±4.5 Not Measured 
BMI 27.9±1.7 30.0±1.8 25.5±5.5 28.0±1.0 31.3±3.8 
                 Table 1 Human Subjects 
Animal subjects 
All animal care and experimental studies were reviewed and approved by the University 
of Texas Health Science Center at Houston Animal Welfare Committee Animal studies 
are reported in compliance with the ARRIVE (Kilkenny et al., 2010; McGrath and Lilley, 
2015), institutional and NIH guidelines. Male C57/BL6 mice 4–5 weeks old weighing 20–
22 g were purchased from Envigo Industries (Indianapolis, IN, USA). All mice were 
housed in ventilated cages equipped with microisolator lids and maintained under strict 
containment protocols. Mice were housed 5 per cage and were provided with variable 
free paper bedding (Pure-o'Cel The Andersons, Inc. Maumee, OH, USA) and Nestlets™ 
provided by Ancare (Bellmore, NY, USA). Mice were kept at an ambient temperature of 
22°C and in a 12 h dark/light cycle. 
 
Hypoxia-sugen 
Mice were kept in a naturally ventilated cage inside a chamber with positive pressure 
(A-Chamber, Biospherix, Lacona, NY) and exposes to 10% oxygen by addition of 
displacing nitrogen for 28 days. Oxygen levels were monitored and controlled by an 
oxygen regulator from OKO Labs (Pozzuoli, NA, Italy). Once weekly 20mg/kg of 
SUGEN (SU5416; Tocirs, Bristol, United Kingdom) was injected intra-peritoneal after 
dissolving in 10% Kolliphor HS 15(Sigma Aldrich, St Louis, MO). Control mice were 
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maintained in room air in the same room. Hemodynamic measures of the mice were 
made at day 28 and samples harvested after they were euthanized.  
 
Bleomycin 
Mice were treated with 0.035 Ug−1 of bleomycin (TEVA Pharmaceuticals, Sellersville, 
PA, USA) or vehicle (PBS; Life Technologies, Grand Island, NY) twice a week for 4 weeks 
i.p On day 15, mice were provided with chow containing 4-MU (Sigma Aldrich, Saint 
Louis, MO, USA), at a dose of 20 mg·kg−1 per day or normal chow (vehicle, Teklad, 
Industries, Indianapolis, IN, USA) for the remainder of the experiment. To deliver 20 
mg·kg−1 per day 4MU was added to the diet at a concentration of 125 mg·kg−1 diet 
(assuming mean body weight ~25 g and intake ~4 g·per day). This was calculated by a 
Nutritionist at Harlan Laboratories (now Envigo). On day 33, physiological readouts 
were performed and the animals were then sacrificed for the collection of tissues and 
fluids for analysis. Mice were assessed bi-weekly for changes in body weight, lack of 
grooming or hunched posture by lab personnel and once-weekly by veterinarians at our 
facility. In a separate cohort of experiments, 4MU therapy (or control chow) began on 
day 33 of BLM exposure and lasted for 14 days. Physiological readouts and tissue 
collection were performed on day 47. 
 
NUDT21 KO Mice 
NUDT21F/F mice were crossed with TaglnCreKI (Taglntm2(cre)Yec/J Jackson Laboratory) 
mice. These NUDT21F/- were used as the experimental group with TaglnCreKI as the 
control group. Mice were age matched.  
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ADA mice 
To generate Ada-/- postnatal mice, an ADA minigene that targeted expression 
specifically to the trophoblast lineage was introduced onto the Ada-/- background. This 
was accomplished by intercrossing mice carrying the trophoblast-specific ADA 
minigene (Tg) with mice heterozygous for the null Ada allele (m1/+). Subsequent 
intercrosses yielded litters that contained mice harboring the ADA minigene (Tg) that 
were also homozygous for the nullAda allele (m1/m1). Given that the regulatory 
elements used targeted Ada expression only to trophoblasts, once born, and with the 
loss of the placenta, Tg-m1/m1 mice lacked ADA enzymatic activity. Mice homozygous 
for the Ada-null allele were designated Ada−/−, while control mice, designated Ada+, 
were heterozygous for the Ada-null allele. Ada−/− and Ada+ mice were congenic on a 
C57BLk/6J background. Male 24-week-old Ada-/- mice or littermate Ada+ controls were 
used for all experiments. 
Ada−/− mice were identified at birth and maintained on ADA enzyme therapy from 
postnatal day (PD) 2 until postnatal day 25 as follows: PD5: 1.25 UI IM, PD9-PD17: 2.5 
UI IM, PD21: 2.5 UI IP, PD25: 5 UI IP. Starting on PD25 mice received weekly doses of 
PEG-ADA (5UI IP) until PD168 (week 24). Mice were randomized to group treatment 
using a random number generator using www.graphpad.com/quickcalcs.  Starting on 
week 24, PEG-ADA was gradually reduced over the course of 9 weeks to 0.125 UI IP as 
follows: week 1: 5UI IP, week 2: 2.5UI IP, week 3 and 4: 1.25UI IP, week 5 and 6: 0.625UI 
IP, week 7 and 8: 0.312 UI IP, week 9: 0.125UI IP. On week 34 mice were provided with 
medicated chow containing 4-Methylumbelliferone (4MU; Sigma Aldrich, Saint Louis, 
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MO) also known as hymecromone at a dose of 20 mg kg-1 body weight (BW) per day-1 
or normal chow (vehicle, Teklad, Industries, Indianapolis, IN) for 4 weeks. During the 
course of these 4 weeks, mice were kept at 0.0125 UI IP of PEG-ADA. On PD 266 (week 
38) physiological readouts were performed and the animals were then sacrificed for the 
collection of tissues and fluids for analysis (details below). 
 
Arterial oxygen saturation 
Physiological assessment measuring arterial oxygen saturation was conducted on 
conscious mice using the pulse MouseOx software analysis (STARR Life Sciences Corp, 
Oakmont, PA). The hair around the neck was removed from mice in order to use the 
collar clip light sensor. The MouseOx provides real-time percent oxygen saturation of 
functional arterial hemoglobin by utilizing pulse oximetry measurements of light 
absorption from the red and infrared LEDs (Light Emitting Diodes). 
 
Hemodynamic measurements 
Right ventricle systolic pressure (RVSP); heart rate and right ventricle (RV) 
hypertrophy. Mice are given 0.75 mg g−1of 5% Avertin (a mixture of tert-amyl alcohol 
and 2–2-2 tribromoethanol, Sigma Aldrich) to induce a surgical plane of anesthesia. 
Mice are placed on a heated surgical workstation (Molecular Imaging Products, Bend, 
OR) and secured with surgical tape. Mice were then tracheotomized with a 19G blunt 
needle (BRICO, Dayton, NJ) and attached to a small animal ventilator (MiniVent, Hugo-
Sachs Elektronik, March-Hugstetten, Germany) and ventilated at a stroke volume of 
250 μL at 200 strokes per minute. The surgical site was viewed using a surgical 
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microscope (SMZ-2B, Nikon, Tokyo, Japan). An incision of ∼1 cm in length was made 
just below the xiphoid process. An alm retractor (ALM-112, Braintree Scientific, 
Braintree, MA) was used to expose the abdominal cavity to visualize the diaphragm and 
the liver. An incision was then made on the diaphragm to expose the heart and the 
pericardium then removed. The right ventricle was then identified and a puncture made 
with a 28G needle. A 1 French pressure catheter (SPR-1000, Millar Instruments, 
Houston, TX) was then inserted through the puncture. Using the same procedure, I 
recorded LVSP, immediately after RVSP measurements. The heart rate results were 
continuously recorded using a Powerlab 8-SP A/D (AD Instruments) converter, 
acquired at 1000 Hz. All RVSP results were recorder to a PC utilizing Chart8 software. 
After completion of the measurements, blood was collected and the lungs were excised 
and flash frozen in liquid nitrogen for RNA extraction. The heart was excised and the 
atria were removed. The right ventricle was then surgically removed and the dry weights 
of the RV were used to determine the extent of RV-hypertrophy (RV/left ventricle [LV] 
+ septum). A heart rate below 250 beats per minute (BPM) during the determination of 
the RVSP or LVSP was considered as a violation of a predetermined criteria. 
 
RT-PCR 
Total RNA was isolated from frozen lung tissue using Trizol reagent (Life Technologies). 
RNA samples were then DNase treated (ArticZymes, Tromso, Norway) and subjected to 
quantitative real-time RT-PCR. Here two technical replicates were performed per 
sample. Prior to RT-PCR experiments RNA quality was evaluated using a Nanodrop 
(Thermo Fisher Scientific, Waltham, MA, USA); to evaluate 260 nm / 280 nm 
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absorbance values. Samples with 260/280 absorbance rations below 1.90 or above 2.10 
were considered to have poor RNA quality and thus violated a predetermined criterion. 
Gene Forward Reverse 
18SrRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
hADA GGGCTGCTGAACGTCATTG AGGCATGTAGTAGTCAAACTTGG 
hADORA1A TGCACTGACTTCTACGGCTG GGTCCCCGTGACCAAACTT 
hADORA2A CGCTCCGGTACAATGGCTT TTGTTCCAACCTAGCATGGGA 
hADORA2B TGCACTGACTTCTACGGCTG GGTCCCCGTGACCAAACTT 
hADORA3 TCATTCTACTCTCCTTGGCTCTC GTGGGCATTGTAGTTGCAGAT 
hCD39 AGGTGCCTATGGCTGGATTAC CCAAAGCTCCAAAGGTTTCCT 
hCD44 AGAAGGTGTGGGCAGAAGAA AAATGCACCATTTCCTGAGA 
hCD73 CCAGTACCAGGGCACTATCTG TGGCTCGATCAGTCCTTCCA 
hCOL1A1 GTGCGATGACGTGATCTGTGA CGGTGGTTTCTTGGTCGGT 
hCOL1A2 GAGCGGTAACAAGGGTGAGC CTTCCCCATTAGGGCCTCTC 
hCOL2A1 TGGACGCCATGAAGGTTTTCT TGGGAGCCAGATTGTCATCTC 
hENT2 GGGGTACTTTATCACGCCCTG GGGAATCCCGTTCTCATCAGA 
hFN1 GGTGGAATAGAGCTCCCAGG GCAGCCTGCATCTGAGTACA 
hHAS1 GAGCCTCTTCGCGTACCTG CCTCCTGGTAGGCGGAGAT 
hHAS1 GAGCCTCTTCGCGTACCTG CCTCCTGGTAGGCGGAGAT 
hHAS2 TCCTGGATCTCATTCCTCAGC TGCACTGAACACACCCAAAATA 
hHAS2 TCCAAAGAGTGTGGTTCCAA GACAGGCTGAGGACGACTTT 
hHAS2Distal CTGGCAGTGTTTTCCCAGAAC CAGGCCACAGAACAAAACCT 
hHAS2Total TCCCGCTGAGACAGATGAGT CAGTGCTCTGAAGGCTGTGT 
hHAS3 CGCAGCAACTTCCATGAGG AGTCGCACACCTGGATGTAGT 
hHAS3 CGCAGCAACTTCCATGAGG AGTCGCACACCTGGATGTAGT 
hHPRT1 TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 
hHYAL2 CACGGGGCTTAGTGAGATG GTCACCCCAGAGGATGACAC 
hIL6 AATTCGGTACATCCTCGACGG TTGGAAGGTTCAGGTTGTTTTCT 
hNRF2 ACACGGTCCACAGCTCATC GCCTCCAAAGTATGTCAATCAA 
hSDHA GAGGCAGGGTTTAATACAGCA CCAGTTGTCCTCCTCCATGT 
hVMA21Distal CATCTGCACAGCACCTTACAGTTTGC 
GAAATGCAGCACATCCAAATCCTC
CC 
hVMA21Total GATAAGGCGGCGCTGAACGCACTGC 
TGAGCCTTCATTCCAGGCCACATAC
ACA 
mADORA2b GCGTCCCGCTCAGGTATAAAG CGGAGTCAATCCAATGCCAAAG 
mFN ACTGGATGGGGTGGGAAT GGAGTGGCACTGTCAACCTC 
mHAS1 GCGAGCACTCACGATCATCTT GTCCATAGCGATCTGAAGCCA 
mHAS2 ACAGATGAGGCAGGGTCAAG TGGGGTGGAAAGAGAGAAGT 
mHYAL1 CCTCAACCCTGCCAGTTTCTC CCCGCTTGTCACACCACTT 
mHyal2 GCAGGACTAGGTCCCATCATC TTCCATGCTACCACAAAGGGT 
mHYAL3 TCTGTGGTATGGAATGTACCCT TTTTGGCCGTGAAAATGTTGG 
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mPPARG GGAAGACCACTCGCATTCCTT GTAATCAGCAACCATTGGGTCA 
mSDHA GGAACACTCCAAAAACAGACCT CCACCACTGGGTATTGAGTAGAA 
Table 2 RT-PCR Primers 
 
Mouse RT-PCR from Prime PCR plates BioRad(Hercules, CA).  
Gene Unique Assay ID 
Actb qMmuCED0027505 
CD44 qMmuCEP0062158 
COL1A1 qMmuCID0021007 
COL1A2 qMmuCID0021177 
COL3A1 qMmuCID0006332 
FN1 qMmuCID0019534 
HAS1 qMmuCIP0036412 
HAS2 qMmuCID0011459 
HAS3 qMmuCID0014012 
HYAL1 qMmuCEP0042433 
HYAL2 qMmuCEP0052809 
NRF2 qMmuCIP0033901 
TBP qMmuCID0040542 
                                                 Table 3 BioRad Primers 
 
 
Immunoblots and ELISA 
For immunoblots protein from lung tissue lysates or PASMC was extracted with RIPA 
buffer (Thermo Scientific, Rockford, IL) containing 1 mM of protease and phosphatase 
inhibitor (Sigma Aldrich). Samples (30 μg protein each) were loaded onto 4–12% Mini-
Protean TGX gels (Bio-Rad, Hercules, CA) for electrophoresis and then transferred on 
polyvinylidene difluoride (PVDF) membranes (0.45 μm, GE Healthcare Piscataway, NJ). 
Membranes were then blocked in 5% milk (Bio-Rad) for 1 h at room temperature and 
then incubated with the appropriate primary antibody overnight. Secondary antibodies 
and an ECL kit from (GE Healthcare) were applied for generating chemiluminescent 
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signals. Blots imaged with the ChemiDoc Touch (Bio-Rad) using optimal auto exposure 
settings. Quantification of these blots were carried out with the Image Lab Software 
(Bio-Rad) to quantify densitometry as well as intensity of target bands and control 
bands. The expression was then calculated relative to control band and output in 
arbitrary units.  
BALF was extracted by flushing the lungs with 0.5 mL of cold PBS twice and collecting 
the fluid using a 1 mL syringe. The presence of blood in BALF was considered as a 
violation of pre-established criteria. Hyaluronan levels in BALF were measured by 
ELISA using a kit from Echelon Biosciences (Salt Lake City, UT), with two technical 
replicates per sample. 
 
Histology and immunohistochemistry (IHC) 
Lung sections 5 microns thick, were dewaxed using histoclear (National Diagnostics, 
Atlanta, GA) and re-hydrated using a gradient of ethanol. Sections were then subject to 
high temperature antigen retrieval using a citrate buffer, endogenous peroxidase and 
alkaline phosphatase were inactivated using BLOXALL (Vector Labs, Burlingame, CA) 
and 2.5% normal horse serum (Vector Labs) was using as a blocking solution prior to 
incubation with the primary antibody. Following overnight incubation with the primary 
antibody, sections were treated with the ImmPRESS polymer detection kits for alkaline 
phosphatase (Vector Labs) based on the host of the primary antibody and developed 
using Vector red or Vector Blue (Vector Labs). For immunofluorescence chicken anti-
mouse Alexa Fluor 488 (Life Technologies Carlsbad, CA) was used and counterstained 
DAPI (Abcam). Lungs stained with Massons's Tri-chrome were analyzed using a 
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modified Ashcroft scale optimized for mouse lung sections. To detect hyaluronic acid, 
sections were incubated with 4 µg/ml of biotinylated HA-binding protein (HABP, 
Calbiochem, 1:125 Darmstadt, Germany) overnight at 4°C, incubated with the ABC kit 
and developed with Vector Blue. For immunofluorescence, sections were incubated 
with SMA and incubated with Alexa Fluor 488 or Alexa Fluor 555 (1:500, Sigma-Aldrich, 
St Louis, MO) sections were counterstained and mounted with DAPI or PI mounting 
media (Sigma-Aldrich, St Louis, MO). 
 
 
Antibody Company Concentration 
αSMA Sigma-Aldrich (clone 1a1) 1:1000 
CD44 Fitzgerald 10R-2062 1:1000 
CD68 Abcam ab125212 1:100 
CFIm59 Proteintech 1:1000 
CFIm68 Proteintech 15489-1-AP 1:1000 
F4/80 Biorad  MCA497 1:500 
GAPDH Thermo Fisher AM4300 1:1000 
GEFT(Human) GeneTex GTX121237 1:1000 
GEFT(Mouse) Santa Cruz sc-16137 1:200 
HABP2 Thermo Fisher PA5-25573 1:100 
Has1 Thermo Fisher PA550674 
1:500 IB  
1:100 IHC 
Has2 Abbexa abx10958 1:200 
Has3 Santa Cruz sc-365322 1:1000 
Hyal1 Santa Cruz sc-1101340 1:200 
Hyal2 Santa Cruz sc-99022 1:200 
NUDT21 Proteintech 10322-1-AP 1:1000 
β-actin Sigma A5316 1:1000 
                        Table 4 Antibodies 
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Morphometry 
Muscularized arterioles of the lung parenchyma were observed under 40× magnification 
and noted as being different from both airways and non-muscularized arterioles. 
Muscularized arterioles were then photographed under 40× magnification. 
Micropictographs were then analyzed using Image Pro-Plus software 
(MediaCybernetics Inc, Bethesda, MD). In short, the overall area of the muscularized 
portion was measured for each arteriole. To correct for size, the largest diameter for 
each arteriole was also measured. The area of the arteriole was then divided by the 
largest diameter to give a relative measurement of muscularization. Poor inflation of 
lungs resulting in a compression of airspaces visualized histologically in normal areas 
of the lung by an observer blinded to group status was considered as a violation of 
predetermined criteria. 
To quantify airspace enlargement, alveolar air-space size was determined in pressure 
infused lungs by measuring mean chord lengths on H&E-stained lung sections. 
Representative images (black and white) were digitized, and a grid consisting of 53 black 
lines at 10.5 µm intervals was overlaid on each image. This line grid was subtracted from 
the black and white lung images using Image-Pro Plus image analysis software (version 
2.0; MediaCybernetics). The resultant lines were measured (in µm) and averaged to give 
the mean chord length of the airspace enlargement. The final mean chord lengths 
represent averages from 10 non-overlapping images of each lung specimen. All 
quantitative studies were performed blinded with regard to animal genotype and 
treatment. It is important to mention that for the quantification of airspace 
enlargement, the images taken were from the parenchyma, devoid of large airway, 
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vascular structures or fibrotic deposition. The exclusion of these structures is necessary 
to quantify airspace enlargement. However, these exclusions were not performed for 
the determination of Ashcroft scores.  
 
RNA-seq  
PASMCs(Lonza) were lysed using TRIzol(Life Technologies) and total RNA purified 
using the RNeasy Kit(QIAGEN). Total RNA-seq was performed with MiSeq(LC 
Sciences). RNA-seq reads were aligned to the human genome(hg19) using TopHat 2.1.1.  
3’UTR APA events between control and NUDT21 siRNA treated cells were identified 
using the DaPars algorithm. This algorithm identifies de novo APA events through the 
use of linear regression models to identify proximal polyadenylation sites and then 
estimates the short and long isoform expression levels using read density upstream and 
downstream of this calculated polyadenylation site (169). Genes with an absolute 
difference of mean PDUIs of no less than 0.1 were identified as having shifted 3′-UTR 
events. Pathway analysis was performed using the ConsensusPathDB-human over-
representation gene set analysis to identify biological networks and functional pathways 
enriched in the dataset.  
 
Liquid Chromatography Tandem Mass Spectrometry 
4-Methylumbelliferone-[13C4] (Toronto Research Chemicals, Ontario, Canada) and 7-
hydroxy coumarin β-D-glucuronide (as sodium salt) (Toronto Research Chemicals, 
Ontario, Canada) were used as the internal standard (IS) for 4MU and 4MUG 
respectively. The stock solutions of a mixture of 4-MU and 4-MUG were diluted in 50% 
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methanol to prepare the spiking solutions ranging from 1 ng mL-1 to 5000 ng mL-1. For 
calibration standards, 25 μL of blank plasma was mixed with 25 μL of the spiking 
solutions. For unknown samples, 25 μL of test plasma was mixed with 25 μL of 50% 
methanol to make up the volume. 25 μL of a mixture of the two IS (1000 ng mL-1 in 50% 
methanol) was also added. After vortexing all standards and samples, 150 μL of 
methanol/acetonitrile 20:80 (v/v) was added to the mixture which was further vortexed 
vigorously for 1 min followed by centrifugation at 850 × g for 10 min. 100 μL of the 
supernatant was diluted with 200 μL of Milli Q water. 
The LC–MS/MS system consists of an AB SCIEX QTRAP 4000 mass spectrometer 
coupled to a Shimadzu UFLC system. Mobile phase A is HPLC grade water. Mobile 
phase B is HPLC grade acetonitrile. LC separation was carried out on a Phenomenex 
Luna PFP(2) column (3 μm, 150 × 2 mm) with isocratic elution using 45% mobile phase 
B and a flow rate of 0.4 mL min-1 at room temperature. The analysis time was 2.5 min. 
5 μL of the extracted sample was injected. The mass spectrometer was operated in the 
negative mode with multiple-reaction monitoring (MRM). The following MRM 
transitions were used: 4MU (m/z 174.7 → 132.9), IS for 4MU (m/z 178.7 → 134.9), 4MUG 
(m/z 350.8 → 174.9) and IS for 4MUG (m/z 336.9 → 160.9). Data acquisition and analysis 
were performed using the Analyst 1.6.1 software (AB SCIEX). 
 
Hyaluronan fragment size assessment 
Lung samples from mice were pulverized and suspended in water. Protease (Pronase 
Calbiochem #537088) was added to a final concentration of 200u mL-1. This was 
digested for 12 h at 55°C. This digestion was repeated six times. Samples were 
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centrifuged at 2400 × g for 10 min. The supernatant was concentrated using Corning 
Spin-X UF concentrators (CLS431477). Samples were mixed with 4 μL 2 M sucrose and 
were run in 0.5% agarose gel in TAE buffer. Hyaluronan size standards were also mixed 
with sucrose. Gel was stained with 0.005% Stains-All (Sigma #E-7762) and then 
destained in water for 48 h. Images were obtained with the BioRad ChemiDoc Touch. 
 
Cell culture experiments and AFM 
Normal control primary PASMC obtained from Dr. Morrell's group (Cambridge, UK) 
were cultured in DMEM with or without 100 μM fasudil (R&D Systems). For studies 
performed to evaluate the proliferative effect and cyotoxcity of hyaluronan and fasudil, 
cells were treated with high molecular weight (HMW; 1350 kDa GLR002 R&D systems, 
Minneapolis, MN), medium molecular weight (MMW, 289 kDa GLR004 R&D systems), 
low molecular weight (LMW, 20 kDa, GLR001) or ultra-low molecular weight (ULMW, 
4.8 kDa GLR003) hyaluronan with or without fasudil (100 μM,). Cell proliferation and 
cytotoxicity was determined using the ApoTox-Glo™ Triplex Assay (Promega, Madison 
WI). This method relies on measuring two protease activities: one for cell viability and 
the other as a marker of cell cytotoxicity. The final part of the assay is the measurement 
of a luminogenic substrate for caspase 3/7. For AFM experiments control and fasudil 
were treated with no hyaluronan, 5.7 mg of medium molecular weight (MMW) 
hyaluronan (R&D Systems GLR004), or 5.7 mg of ULMW hyaluronan (R&D Systems 
GLR003). After 24 h the cells were used for AFM measurements at room temperature. 
The force curves measurements were performed with a Catalyst Bioscope System 
(Bruker Corporation, Billerica, MA). The AFM was equipped with an inverted light 
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microscope (Olympus IX81) so that the cells were constantly monitored. Silicon nitride 
cantilevers (Novascan Technologies, Inc., Ames, IA) with approximate spring constant 
values of 0.06 N m−1 were employed in all AFM experimentations. The AFM probe was 
purchased from Novascan (the probe has a silicon nitrite cantilever with a 5μm silica 
spherical particle on the end) with a spring constant of 0.06 N s−1. The cantilever 
sensitivity was calibrated with the NanoScope 9.0 software by measuring a force curve 
on a clean silicon wafer. Force curves were acquired at a sampling rate of 1 Hz. The 
Young's modulus, E, was calculated from obtained force curves based on the Hertzian 
fit mode using Nanoscope analysis program from the Bruker Corporation. F = 
2πE1−υ2tanαδ2 where F = force, E = Young's modulus, ν = Poisson's ratio (ν = 0.5, in this 
study), α = half-angle of the indenter (i.e. tip radius, α = 5000 nm, in this study), and δ 
= indentation depth. 
 
Cell culture experiments 
The mouse alveolar macrophage cell line MH-S (ATCC, Manassas, VA, USA) was 
maintained at 37°C and 5% CO2. MH-S cells were grown in RPMI-1640 supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine and penicillin-
streptomycin. For experimental use, MH-S were serum-starved overnight in RPMI-1640 
supplemented with 2% FBS, 2 mM L-glutamine and penicillin-streptomycin, followed 
by 24h exposure to ADORA2B agonist BAY60-6583 (10 µM, Tocris) with or without the 
ADORA2B antagonist GS6201 (100 nM, Tocris). PASMCs were maintained in in similar 
conditions with starvation occurring for 48hr coinciding with siRNA or plasmid 
transfection. Proliferation assay occurred with 0 or 25mM BB-PDGF while migration 
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occurred with no serum gradient at 1% FBS or with a gradient from 1-10% FBS in boyden 
chambers with 8um pore size. 
 
PASMC isolation  
The pulmonary arteries are dissected out of the tissue. The adventitia is then removed 
with forceps. The arteries are bisected longitudinally and then treated with 4mL of 
digestion mixture. Digestion mixture is a mixture of 4mL of Collagenase Type 
II(2mg/mL) and 75 µL of elastase(125U/µL) for about 2 hours. The cells are then grown 
in Smooth Muscle Growth Medium(ScienceCell). Cells are used at passage three or 
passage 4.  
 
NUDT21 depletion and overexpression 
For NUDT21 overexpression the coding region was cloned into the pCDNA3.1 +C 
plasmid. 5µg of plasmid or empty vector was transfected using jetPRIME(Polyplus New 
York, NY) into a 80% confluent 10cm twice 24hr separated. Depletion was performed 
with siRNAs purchased from Sigma-Aldrich(Human NM_007006 260 MISSION siRNA 
4) with the same time points and 500pmoles of siRNA. 
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